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Glossary and abbreviations 
TCC : Transitional Cell Carcinoma 
TURT : Transurethral Resection of Tumor 
FCM : Flowcytometry 
BGI : Blood Group Isoantigens 
SRCA-test : Specific Red Cell Adherence-test 
TNM Staging System ' 
Τ : Primary Tumor 
N : Regional and Juxta-regional Lymph Nodes 
M : Distant Metastases 
Tis : Carcinoma in situ, pre-invasive 
Ta : Papillary non-invasive carcinoma 
Tl : The tumor does not invade beyond the submucosal connective tissue 
T2 : There is microscopic invasion of superficial muscle 
T3 : Invasion of deep muscle or extension through the bladder wall 
T4 : Tumor fixed or extending to neighbouring structures 
The suffix (m) may be added to the appropriate Τ category to indicate multiple tumors, 
e.g. T2 (m). 
WHO Grading System2 
G1 :Low grade tumors with the least degree of cellular anaplasia, compatible with 
a diagnosis of malignancy 
G2 ¡Intermediate degree of cellular anaplasia 
G3 :High grade tumors with the most severe degree of cellular anaplasia 
Some examples of cytogenetic nomenclature3 
Karyotype : 
47,XY,+21 : 
45,XX,-8 : 
47,XY,+14p+ 
47,XX, + lq- : 
Chromosome* 1 
2n: 
del: 
t(8;14) : 
A systematic arrangement of the chromosomes into various groups 
according to size, centromere location and banding patterns obtained 
after differential staining procedures 
47 chromosomes, XY sex chromosomes and an additional 
chromosome # 2 1 
45 chromosomes, XX sex chromosomes and a missing chromosome 
# 8 
Male karyotype with 47 chromosomes including an additional 
chromosome #14 which has an increase in the length of its short arm 
Female karyotype with 47 chromosomes including an additional 
chromosome # 1 which has a loss of length of its long arm 
Chromosome number 1 
Diploid number of chromosomes, in the human beings 46 
Deletion, loss of a chromosome part 
Translocation between chromosomes#8 and #14; breakage, 
followed by exchange of chromosome material between these 
chromosomes 
5 
Triploid . All the chromosomes are present in the triplicate, i.e 69 
chromosomes (3n) 
Near diploid : The modal number cannot be given as a precise number (2n ±) 
Pseudodiploid: The modal number of chromosomes is equal to the diploid number 
(for human beings 46), but numerical and/or structural aberrations 
are present 
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Chapter I 
Introduction 
Histopathological prognostic factors in bladder cancer. 
Bladder cancer, after prostatic cancer the most common cancer seen in urology1, can 
basically be segregated in three forms: the papillary transitional cell carcinoma, a deeply 
invasive form that often disseminates, and carcinoma in situ2"6. The most important single 
factor affecting prognosis is the extent of spread or stage of the tumor.3·4'7"13. The depth 
of invasion in the bladder wall or into adjacent tissues by the neoplasm correlates with the 
presence of metastases, and this implies the potential for cure.8-10'14"16 However, in the 
majority of patients presenting for the first time with bladder cancer, the tumor is 
papillary, superficial and shows no invasion or only invasion in the submucosal connective 
tissue. ^ 17 Most (50 - 80%) of these tumors recur and some, varying from 3 per cent for Ta 
tumors to 44 per cent for T l tumors, do so in a more advanced, potentially lethal stage. 
2,i7-2i Therapeutic efforts are directed towards conserving the bladder as long as possible, 
recognizing that although bladder tumors recur frequently, many patients will have an 
indolent clinical course. Common practice is to delay radical therapy (radiotherapy and/or 
cystectomy) until muscle invasion has been clearly documented. Unfortunately, when 
this event has occurred, five-year survival is only 40 to 50 per cent regardless of the use of 
preoperative radiation or the extent of surgical extirpation. ^10'13'22-2'' Systemic 
dissemination has already occurred in many of these patients and is reflected in the 
appearance of distant metastases within 18 months.25 So the heterogeneity of superficial 
bladder tumors is clinically manifest in varying patterns of recurrence and prognosis, and 
in varying responses to surgical extirpation, radiation or chemotherapy. Therefore, in 
transitional cell carcinoma, the pathologist, in addition to his task of establishing the 
diagnosis, is asked to predict the biologic potential of the tumor. He than has to identify 
patients with non-invasive disease with the greatest risk of recurrence with or without 
invasion, and to identify patients with invasive disease with the greatest risk of 
dissemination and death of tumor. To allow the pathologist to make an accurate statement 
with respect to the depth of invasion of the tumor, a biopsy must include a sufficient 
amount of muscle tissue. A superficial transitional cell carcinoma (T.C.C.), the object of 
this thesis, has an exophytic, papillary growth pattern. Even in a deep biopsy specimen 
including muscle, the recognition of invasion of the lamina propria may be difficult for the 
pathologist.26 So there is a need for other prognostic criteria, additional to tumor stage. 
Additional histopathological characteristics reported to have predictive value are tumor 
grade27'28, number and size of visible tumors2'21 associated mucosal abnormalities 
elsewhere in the bladder17'20'29 and for tumors once recurring a high recurrence rate30 and 
the presentation of higher graded recurrences.31,32 Of all these parameters, tumor grade is 
the most important. 
The concept of tumor grade was introduced by Broders33'34 who subdivided squamous 
cell carcinoma in four groups, depending on the degree of differentiation of the cells. 
Grading of bladder tumors appeared to be of great prognostic value. 27'28>32 For bladder 
cancer, several grading systems have been described.26-28'34"37 Generally transitional cell 
carcinoma of the bladder is divided in three grades; grade 1 or low grade carcinoma, grade 
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2 carcinoma of intermediate grade, and grade 3 or high grade cancer. When a fourth grade 
is used this applies to undifferentiated tumors. Either these grade 4 tumors are not 
recognized as primary urothelial tumors, or they should be classified as TCC grade 3.2 8 As 
not everyone accepts the same pathological criteria for the diagnosis of malignancy26, the 
definition of what is a grade 1 or low grade tumor varies. For some a grade 1 papillary 
lesion shows only thickened urothelium, without significant nuclear abnormalities.27'28 
For others grade 1 applies to tumors that have "the least degree of cellular anaplasia 
compatible with a diagnosis of malignancy"26 or nuclear pleomorphism and disturbance 
of cellular architecture.37 Generally, the clinical course of grade 1 tumors is rather 
innocent, for grade 3 tumors poor. There appears to be a variable interpretation of the 
intermediate grade 2 neoplasms. Often pathologists classify tumors as being grade 1-2, or 
grade 2-3, in correlation with the clinical presentation of "good" and "bad" tumors of 
moderate grade.28 Even when using the same grading system, the grade given to a 
particular tumor may vary between different pathologists, and occasionally for the same 
pathologist on different days.38 The study by Ooms and associates 38 revealed that about 
50 per cent of all tumors were graded in a significant different manner by the same 
reviewer after 7 months. Thus grading is rather subjective, requiring a referee pathologist 
in comparing final results of different treatment modalities, or of the same treatment in 
different institutions. These problems of terminology and interpretation for many years 
hampered communications about superficial bladder tumors between urologists and 
pathologists of different institutions. Much more information about the biology of bladder 
cancer is needed to support the morphological criteria like low and intermediate grade. 
The variability in tumor grading, and especially the heterogeneity of superficial 
intermediate grade tumors prompted this study for a reliable and reproducible 
histopathological, clinically relevant distinction within these grade 2 neoplasms. That is 
one objective of this thesis. 
Additional tumor markers 
The shortcomings of traditional histopathological parameters in the heterogeneous group 
of superficial bladder cancers made additional tumor markers urgently needed. Tumor 
markers can be substances produced by the tumor itself and secreted into the body fluids. 
As such markers in TCC were mentioned for instance carcinoembryonic antigen39 
polyamines40, rheumatoid factors 41, fibrin degradation products 42 and tryptophan 
metabolites. 43 Most of the putative tumor markers detectable in blood or urine have not 
fulfilled their earlier promise in bladder cancer.42'44"51 Tumor markers also may be 
noncirculating substances, confined to the malignant cell itself. As most sensitive cellular 
tumor markers in bladder cancer were reported chromosomal abnormalities 48'52"54) 
cytometric DNA-values55"60, and the ABO (H) blood group antigens.61"65 
Chromosomes and bladder cancer 
The idea that chromosomes play a role in malignant cell growth is an old one. ^-69 
Cytogenetic experts were only able to recognize chromosomal abnormalities in tumors in 
a reliable and reproducible way after the introduction of differential staining techniques. 
Microscopic analysis of the banded chromosomes is most easily done in the metaphase. 
Terminology and classification of chromosomes and their abnormalities were 
standardized and summarized in "An International System for Human Cytogenetic 
Nomenclature".70 The chromosomes are numbered and divided into seven groups (A -
G), each group with chromosomes that are morphologically more or less similar. Banding 
techniques make identification of individual chromosomes possible, and can be used to 
demonstrate abnormalities of chromosomes that seem normal with conventional staining 
methods.71'72 Several techniques frequently used are: 
G-banding: named after Giemsa, the most widely applied stain; this method produces 
Ught and dark bands which are visible with the light microscope, after various forms of 
pretreatment; 
Q-banding: more or less the same type of pattern can be produced, without pretreatment, 
by Quinacrine (mustard) stain, only visible however in fluorescence microscopy; 
C-banding: method to stain the constitutive heterochromatine which is located around the 
centromeres and in the distal part of the long arm of the Y chromosome and can vary 
among individuals. 
The cytogenetically recognisable abnormalities in tumors are of three kinds: 
- numerical abnormalities i.e. any abnormality in the number of chromosomes, 
(aneuploidy; polyploidy); 
- structural abnormalities; a chromosome resulting from a structural abnormality that 
cannot be identified, is called a marker chromosome; 
- fragmentation of chromosomes in minutes and double minutes. 
Well known examples of chromosomal abnormalities that are more or less specific for a 
certain neoplasm are the Philadelphia chromosome, which is the result of a translocation 
between chromosome number 22 and number 9 in chronic myeloid leukemia73, and the 
translocation t(8;14) in the Burkitt lymphoma.74 
The first report about cytogenetic analysis in bladder cancer cells was made by Spriggs 
and associates75, mentioning chromosomal abnormalities in peritoneal effusions of two 
patients. Larger series followed soon.76'77 An increase in chromosome number appeared 
associated with higher graded tumors, malignancy and infiltration.77'78 Structural 
abnormal chromosomes were found77 which, in superficial bladder cancer, were 
mentioned as reliable prognostic parameters in individual patients.52"54'79 Cytogenetic 
examination of bladder carcinoma may therefore in a very early stage produce a most 
sensitive and specific tumor marker with respect to future behavior. The reported 
correlation between cytogenetic data and tumor grade, and the biologic potential for 
recurrence and invasion led to the decision to study chromosomal abnormalities as an 
objective basis for grading or prognosis. 
Karyotypic changes can be a reflection of alterations in the location of oncogenes. 73>74·80-86 
These karyotypic changes can occur as translocations, amplifications, deletions or fine 
structural alterations. They are at least markers of essential genetic events. Primary 
karyotypic changes are possibly an expression of primary oncogenetic processes, of 
importance in the etiology of the cancer87 Specific karyotypic aberrations can also be 
secondary and reflecting tumor events or chromosomal selections later in time, parallel to 
the biological behavior of tumors as their capacity to invasion, metastatic spread and 
reactions to therapy.88 Recently in bladder tumors nonrandom chromosomal changes 
have been demonstrated.89 Until now cytogenetic analysis in bladder cancer did not 
identify the earliest irreversible changes predicting invasion and metastasis. Therefore 
banding techniques were applied in a number of bladder tumors described in this thesis to 
see whether nonrandom abnormalities in the chromosomes could be demonstrated. 
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Preceding the analysis of chromosomal changes in bladder cancer, a useful technique to 
obtain recognizable chromosomes from as many tumor specimens as possible was 
developed. This technical aspect is reported elsewhere. 90,91 In this thesis the correlations 
between cytogenetic data, tumor grade, and the biological behavior of superficial bladder 
cancer are analyzed. 
ABH antigen deletion 
Another biological marker which is reported to reflect cellular differentiation and the 
maügnant potential of a tumor is the presence or absence of certain cell surface antigens 
such as the ABH blood group isoantigens (BGI). In normal urothelium the cell 
membranes are rich in ABH blood group antigens92'93 and it was suggested that the 
presence or absence of these substances in TCC might have prognostic value. 61-63>94·95 Loss 
of these isoantigens in metastatic bladder carcinoma appeared to be quite common.62 This 
however is not the case with nonmetastatic disease. In superficial TCC of the bladder loss 
of these antigens is stated to occur especially in tumors which carry a poor prognosis with 
respect to invasion and metastasis. 63>65>96-98 Catalona M in a survey on studies on BGI-
deletion, concluded that testing for blood group antigens was not useful in predicting 
recurrences. Most authors mentioned however a clear correlation between antigen content 
and other aspects of tumor behavior. Thus, at the start of our study on ABH antigen status 
in bladder tumors, it was generally believed that the determination of ABH antigen 
expression in urinary bladder carcinoma might be helpful in discriminating between those 
patients with superficial bladder carcinoma who are at low risk for subsequent tumor 
invasion from those at relatively high risk, for whom early aggressive therapy might be 
justified. 
However, studies on ABH antigen status had serious limitations. In many of these studies 
the proportion of low grade, low stage carcinomas that later became invasive was 
surprisingly high, compared with the percentage seen in common clinical practice.4'17 In 
addition, the lack of satisfactory methodology for detecting the antigens in tissue sections, 
and the subjectivity in the interpretation of test-results hampered wide-spread clinical 
implementation of assessing BGI deletion in bladder tumors. 
The initial studies on BGI deletion employed the specific red cell adherence (SRCA) test, 
developed from the mixed red cell agglutination test. " This test involves adherence of 
erythrocytes to the appropriate antigens in a tissue section. Since antibody to antigen H in 
the membranes of blood group О patients was not readily available, a lectin was 
substituted, extracted from the seeds of Ulex Europaeus, a leguminous shrub. ""'•К'1 This 
lectin crossreacts with the weakly immunogenic antigen H and therefore can replace the 
antibody for antigen H. The relatively small size of4he Ulex lectin molecule that is used to 
detect antigen H makes the SRCA-test less sensitive in blood group О patients with much 
more false negatives, than is the case for patients with blood group A and B. 9 8 ' 1 0 2 In 
addition the SRCA-technique gives a limited resolution because of the large size of the 
indicator particles, erythrocytes. Therefore the test is difficult to standardize and 
interpret. 
Because of the limitations of the SRCA-technique, we preferred the immunoperoxidase 
method.103,1<>4 This technique offers an increased sensitivity for the H antigen and a 
superior resolution. A practical advantage of the immunoperoxidase procedure is that this 
method lends itself to the processing of large batches of slides simultaneously. It was 
already routinely used in our pathology laboratory to demonstrate hormones and other 
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substances in tissue sections. However, also in the immunoperoxidase method Ulex lectin 
was routinely used for detection of the H tissue antigen. With this method anti-lectin-
antiserum is the secondary antibody, linking with the horse-radish peroxidase 
chromophore third antibody. This lectin-antiserum presumably combines at multiple 
sites on the lectin molecule which makes the sensitivity of the immunoperoxidase 
technique greater.105 To our great disappointment the need to use a lectin in detecting the 
H isoantigen, together with variation in specificity found with conventional polyclonal 
blood group antisera, limited the reliability and reproducibility of the immunoperoxidase 
technique. Conventional polyclonal antisera such as those obtained from the 
immunisation of animals invariably consist of a heterogeneous mixture of antibodies to 
more than one antigen. 
In 1975 a technique was described to produce monoclonal antibodies (McAb's) with the 
use of immunoglobulin-secreting mouse hybridoma cell lines. 1 0 6 This led to the 
production of pure, homogeneous and highly specific reagents to the А, В and H 
isoantigens. Experience with the use of McAb's as primary antibodies in larger series of 
bladder cancer was not yet available. So we started a study on BGI-deletion in superficial 
bladder cancer using the indirect immunoperoxidase method with McAb's, to see whether 
testing for ABH-antigen status could fulfil the earlier promise of producing an additional 
tumor marker in superficial TCC. Our original goal was to examine, at first tumor 
presentation, an additional parameter to predict future tumor behavior. In this thesis 
presence or absence of blood group isoantigens in superficial TCC of the bladder is 
correlated with tumor stage and grade, chromosomal numbers and clinical course. 
Aims of the present study 
Primary aim of this study was the investigation of predictors of the clinical course 
additional to tumor stage, in superficial transitional cell carcinoma of the bladder. Because 
of the variability of grading a prospective study was carried out in which the intermediate 
grade tumors were separated in two subgroups to see whether it is possible to make a 
sharper histopathological, clinically relevant distinction between low and intermediate 
grade bladder tumors. 
A study of the chromosomes in bladder cancer was done in order to obtain more 
information about biological characteristics of these tumors, to investigate the prognostic 
value of chromosomal abnormalities, and to examine whether a correlation between our 
grading criteria and the results of cytogenetic analysis can be demonstrated. 
Next, an analysis of cellular ABH blood group antigens in bladder cancer was done, using 
the indirect immunoperoxidase technique with monoclonal antibodies. This was 
correlated with tumor grade, chromosomal number and clinical course in superficial 
tumors. Aim was to investigate whether with the use of this essay a correlation was 
demonstrable between ABH antigenstatus and our grading criteria, or whether ABH 
antigen- testing had additional prognostic value. 
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Abstract 
Tissue specimens from 96 patients with urothelial cell carcinoma were subjected to 
cytogenetic examination to determine whether there is a correlation between 
chromosomal abnormalities and tumor behavior. Recognizable metaphases were found in 
43 patients (45 per cent). The range in chromosomal counts appeared to be a better 
reflection of invasion than the modal number. Noninvasive tumors nearly always were 
hypodiploid or diploid. All invasive tumors showed hyperploid cells. Cytogcnetically, 
there was no difference between invasive grade 2 and grade 3 tumors. During our limited 
follow- up tumor progression was found only in tumors with hyperploid cells. With a 
direct technique we found no difference in the frequency of marker chromosomes 
according to tumor stage and grade. 
Introduction 
Transitional cell carcinoma of the urothelium has an unpredictable natural history with 
respect to recurrence and invasiveness of superficial lesions.1 In daily urological practice 
the most important predictors of the clinical behavior of urothelial cell carcinomas are 
tumor stage and grade. However, the histopathological terminology is not well 
standardized, and cannot predict which superficial bladder tumors will recur and become 
invasive.2 An additional parameter for the prognosis might be obtained from cytogenetic 
studies.3,4 The probability of recurrence or invasion may be linked to the presence of 
numerical or structural chromosome abnormalities. In early studies an increase in modal 
chromosome number (hyperploidy) was associated with malignancy and infiltration.5'6 
Spooner and Cooper found that well and moderately well differentiated tumors fell within 
the diploid range (42 to 49 chromosomes), whereas the majority of poorly differentiated 
cancers showed a widespread distribution of chromosome numbers.6 Falor7 and others4,8,9 
found a large number of structural abnormalities, including marker chromosomes, 
especially in poorly differentiated and invasive tumors. Low stage, low grade carcinomas 
of the bladder nearly always were diploid or near diploid (42 to 49 chromosomes), 
although a few marker chromosomes were observed.4,10 
In regard to the prognosis in superficial bladder carcinoma, Summers and associates 
concluded that patients with hyperploidy especially appear to be at a high risk for 
subsequent invasion.4 Granberg-Öhman and associates stated that tumors with a diploid 
mode also could become progressive.9 Many investigators have stressed the prognostic 
importance of marker chromosomes, especially in tumors with a chromosome number in 
the diploid range.3,8,9,11 Falor and Ward mentioned that the modal number of the tumor 
so closely mirrors the presence of markers that the number hardly affords additional 
information with respect to the prognosis.11 This discrepancy as to the meaning of 
chromosomal abnormalities, especially in low stage, low grade bladder tumors, clearly 
shows the need for more follow up to reveal the biological significance of the reported 
chromosomal aberrations. 
We performed chromosome analysis in relation to stage, grade and tumor behavior. 
Materials and methods 
Between January 1981 and June 1984, tissue specimens from 96 patients with transitional 
cell carcinoma (91 in the bladder, 3 ureter and 2 pelvis) were subjected to chromosomal 
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examination. The patients were followed until December 1985, or until tumor progression 
or treatment with intravesical chemotherapy. Included were 14 patients who already had 
a recurrent tumor. None of these patients had been treated previously with radiotherapy 
or intravesical chemotherapy. Tissue was taken by transurethral resection, as well as by 
cold punch biopsy. A portion of each biopsy was sent to the pathology anatomy laboratory 
and another was sent to the cytogenetic laboratory. 
A direct technique was used for chromosomal analysis and, if enough tumor material was 
available, a short-term culture was applied. The detailed procedure with an evaluation of 
the techniques used has been reported previously.12 For the direct method material was 
collected in 0.9 per cent sodium chloride with 1 μg./mi. colchicine. After incubation for 
30 minutes at 370C, mechanical disaggregation of the tissue and preparation of a cell 
suspension were done. Hypotonic treatment in 0.075 M. potassium chloride was followed 
by fixation in methanol-acetic acid 3:1. During the last year a direct squash technique was 
used. 
As a short-term culture the material was incubated for 24 hours in tissue culture RPMI-
1640 medium plus 15 per cent fetal calf serum and 4 per cent penicillin-streptomycin 
(5,000 units per ml.) at 370C. Two hours before termination of the culture 0.1 ^ig./ml. 
colchicine was added, followed by hypotonic treatment and fixation. The preparations 
were stained with the Giemsa method. If sufficient slides were available and the unhanded 
preparations showed good metaphases, СB.G.-banding and G.T.G.-banding methods 
were used. Normal bladder tissue was rather solid and usually could not be worked well 
into a cell suspension for the direct technique. The specimen was subjected to a long-term 
culture in Ham's-FlO medium with 15 to 25 per cent fetal calf serum in a 5 per cent carbon 
dioxide and 95 per cent air atmosphere for 1 to 4 weeks. Analyzable metaphases were 
photographed and karyotyped according to the Denver and Paris nomenclature.13 Cells in 
metaphase were considered to be analyzable if there were none or only a few overlapping 
chromosomes and the number of chromosomes at least could be counted. If the number of 
chromosomes was in the diploid range it was considered necessary to recognize the A to G 
groups. 
According to the chromosome number the tumors were classified as to 1) the modal 
numbers, that is hypodiploid (less than 46 chromosomes), diploid (46), hyperdiploid (47 
to 57), near triploid (58 to 80), near tetraploid (81 to 103) and hypertetraploid (more than 
103), and 2) whether the tumors had cells only in the hypodiploid or peridiploid range (49 
or less), and cells with more than 49 chromosomes (hypcrploid). Marker chromosomes 
were classified according to the position of the centromere.14 
Clinical staging of the tumor was done according to the tumor, nodes, and metastasis 
classification,15 and grading was done according to the World Health Organization 
grading system.16 
Results 
A summary of the 96 cases according to tumor stage and grade, and the number of patients 
with countable metaphases is shown in table 1. When applied, the direct and the short-
term culture techniques revealed identical chromosomal abnormalities. Therefore, these 
results were pooled. The number of metaphases varied between 3 and a large amount per 
tumor, or between 1 and approximately 25 per slide. 
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Table 1 
Patients examined and countable metaphases 
Grade 1 
Grade 2 
Grade 3 
Totals 
pTa 
4/-
48/18 
1/ 
53/18(34) 
pTl 
-I-
14/5 
4/3 
18/8(44) 
Stage 
pT2 
-/ 
3/2 
4/4 
7/6(85) 
pT3 
-/-
9/7 
8/4 
17/11(65) 
pT4 
-/-
-/-
1/-
1/. 
Totals 
4/-
74/32(43) 
18/11(61) 
96/43(45) 
Values are given as number of patients examined/number of patients with recognizable chromosomes (per cent 
of those examined) 
Countable metaphases were found m 43 of 96 tumors (45 per cent). During the last year of 
our study this value increased to 70 per cent. However, mitoses that included metaphases 
not suitable for further chromosomal analysis were seen in 70 of the tumors exammed (73 
per cent)· 34 of 53 (64 per cent) noninvasive and 36 of 43 (84 per cent) invasive tumors. 
Multiple tumors did not show mitoses more frequently than the single carcinomas even if 
more biopsies were done Usable metaphases were seen in 18 of 5 3 (34 per cent) non-infil-
trating, 8 of 18 (44 per cent) superficially invasive and 17 of 25 (68 per cent) deeply 
infiltrating tumors. These results show a tendency that in deeper growing tumors (stages 
T2 and T3) the yield of recognizable metaphases is higher (chi-square test for trend, ρ = 
0.001). A same tendency was seen for higher grade tumors. Among the 18 non-mvasive 
tumors (stage pTa) mostly hypodiploid of diploid metaphases were noted (tables 2 and 3). 
The 8 superficially infiltrating tumors (stage pTl) showed a wide range m modal number. 
The 17 deeply infiltrating tumors (stages pT2 and pT3) were mostly in the triploid or 
tetraploid range, although 4 showed a diploid modal number Of the 32 moderately well 
differentiated tumors 21 were hypodiploid or diploid Among the grade 2 tumors the 
noninvasive lesions were mostly but not all hypodiploid or diploid, while the invasive 
tumors showed a wider range in modal number 
Separately, a distinction was made in tumors with cells only containing 49 or less 
chromosomes, and in tumors with at least 1 cell contaming more than 49 chromosomes. 
Of 18 non-invasive tumors 14 had only cells with 49 or less chromosomes (table 3). 
Table 2 
Cytogenetic data in 
Pt 
No 
1 
2 
3 
4 
5 
6 
7 
8 
Stage 
Ta(m) 
Ta 
Ta(m) 
Ta 
Ta 
Ta 
Ta 
Ta 
143 patients 
Grade 
2 
2 
2 
2 
2 
2 
2 
2 
No Countable 
Metaphases 
(range) 
3(46) 
4(46) 
3(36-45) 
4(30-46) 
4(35 48) 
7(43-46) 
5(45 46) 
75(32-49) 
Moda 
No 
46 
46 
45 
43 
46 
44 
46 
46 
1 
η 
-
-
-
1 
-
-
1 
Ploie 
2n 
3 
4 
3 
3 
4 
7 
5 
74 
ly(n = 
3n 
-
-
-
-
-
= 23± 
4n 
-
-
-
-
-
-
l i e t e ) 
5n 
-
-
-
-
-
-
Marker* 
. 
-
submedian 
-
submedian 
-
-
submedian 
and median 
Banding-
Technique** 
-
-
-
-
C/G 
С 
Та 10(34 46) 46 10 
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Pt. 
No. 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
Stage 
Ta(m) 
Ta 
Ta 
Ta 
Ta 
Ta 
Ta(m) 
Ta(m) 
Ta 
Tl(m) 
T l 
T l 
Tl 
Tl(m) 
Tl 
Tl 
Tl(m) 
T2 
T2 
T2 
T2 
T2 
T2 
T3(m) 
T3 
T3 
T3 
T3 
T3 
T3 
T3 
T3 
T3 
T3 
Grade 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
3 
3 
3 
2 
2 
3 
3 
3 
3 
2 
2 
2 
2 
2 
2 
2 
3 
3 
3 
3 
No Countable 
Metaphases 
(range) 
46(38-46) 
13(36-46) 
5(42-44) 
8(46-48) 
35(23-44) 
25(40-90) 
16(35-71) 
22(38-78) 
13(50-90) 
11(35-72) 
16(28-73) 
40(35-72) 
50(34-56) 
48(46-92) 
6(70-89) 
3(90-95) 
15(23-80) 
33(43-75) 
18(38-78) 
6(50-93) 
25(50-220) 
29(36-90) 
6(42-70) 
4(41-56) 
3(46-100) 
13(65-80) 
3(90-95) 
10(40-62) 
14(42-90) 
8(46-90) 
3(50-90) 
5(42-90) 
10(64-90) 
21(37-90) 
Moda 
No. 
46 
44 
43 
48 
40 
43 
43/70 
43 
67 
65 
53 
42 
44 
46 
80 
92 
46 
46 
70 
69 
115 
69 
46 
46 
69 
73 
92 
46 
69 
69 
69 
69 
75 
90 
il 
η 
_ 
-
-
-
4 
-
-
-
-
2 
-
2 
-
-
-
4 
-
. 
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Ploidy(n = 
2n 3n 
46 
13 
5 
8 
31 
19 
8 
19 
2 
4 
9 
38 
48 
38 
-
-
7 
27 
6 
3 
-
17 
5 
4 
1 
-
-
9 
10 
6 
1 
3 
-
4 
_ 
-
-
-
-
1 
8 
3 
7 
7 
5 
2 
-
6 
3 
-
4 
6 
12 
-
-
2 
1 
-
1 
13 
-
1 
-
-
1 
-
5 
4 
= 23± 
4n 
-
-
-
-
-
5 
-
-
4 
-
-
-
4 
3 
3 
-
-
3 
15 
10 
-
-
1 
-
3 
-
4 
2 
1 
2 
5 
13 
l i e t e ) 
5n 
. 
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
. 
10 
-
-
-
-
-
-
-
-
-
-
-
-
-
Marker* 
_ 
-
-
-
submedian 
submedian 
-
-
subterminal 
submedian, 
median and 
terminal 
subterminal 
submedian 
subterminal 
and median 
-
terminal 
-
-
-
submedian, 
subterminal 
and terminal 
terminal 
subterminal 
and terminal 
median 
-
terminal 
-
subterminal 
-
-
-
-
terminal 
-
-
-
Banding-
Techmque** 
C/G 
-
-
-
G 
-
-
-
-
-
-
С 
-
-
-
-
-
С 
-
-
-
-
-
-
-
-
-
-
-
-
-
(m): 
Unidentifiable structurally abnormal chromosome with the centromere in the submedian, median, 
subterminal or terminal region 
Procedures of differential staining technique by which various intrachromosomal bands and/or regions can 
be made visible, such as G-banding by Giemsa staining 
C-bands are dark staining condensed regions corresponding in position mainly to the centromeric region. 
Multifocal 
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Table 3 
Tumor stage and grade in relation to modal number of chromosomes and to number of chromosomes in 
individual cells 
Stage Grade 2 
Total No. Grade 3 
otal No. tumors 
odalNo.. 
Hypodiploid 
Diploid 
Hyperdiploid 
Near tnploid 
Near tetraploid 
Hypertetraploid 
o. chromosomes: 
« 4 9 
> 4 9 
43 
10 
13 
3 
13 
3 
1 
14 
29 
pTa 
18 
8 
7 
2 
1 
-
-
14 
4 
pTl 
8 
2 
2 
1 
2 
1 
-
-
8 
pT2-pT3 
17 
-
4 
-
10 
2 
1 
-
17 
Non-invasive 
18 
8 
7 
2 
1 
-
-
14 
4 
Invasive 
14 
2 
4 
1 
6 
1 
-
-
14 
11 
-
2 
-
6 
2 
1 
-
11 
All 25 superficially (stage pTl) or deeply (stages pT2 and pT3) infiltrating tumors had 
hyperploid cells. The difference in chromosome counts according to this distinction, 
between non-invasive (stage pTa) and invasive tumors, is highly significant (Krushal-
Wallis test ρ = 0.0002). According to the number of chromosomes no significant 
difference between submucosal (stage pTl) or deeply infiltrating tumors was found. All 
invasive grade 2 carcinomas showed cells with more than 49 chromosomes, as did all grade 
3 tumors. Of the 18 stage pTa grade 2 tumors, 4 were hyperploid (more than 49 
chromosomes). Patient 18 had inoperable disease and did not tolerate intravesical 
chemotherapy. Patient 15 had a follow up of 13 months and no recurrence. The other 2 
patients had recurrences (patient 17 with progression to a stage pTl tumor after 50 months 
of follow up). 
Marker chromosomes 
Marker chromosomes were established by conventional chromosome staining without 
special banding techniques and were found in 18 of the 43 patients: 6 of 18 (33 per cent) 
with stage Ta and 12 of 25 (48 per cent) with invasive tumors (table 2). There was no 
difference in the frequency of markers according to tumor grade. 
In 8 patients a large marker was found with the centromere in the submedian region. This 
chromosome varied in size compared to the Al chromosome (fig. 1). A loss of an A and 
C-group chromosome often was associated with the presence of this marker. In patient 14 
the marker was banded. Unfortunately, the pattern could not be interpreted fully. The 
markers with the centromere in the subterminal and terminal regions were found mostly 
in more infiltrating tumors (fig.2). The markers with the centromere in the median region 
were found in noninfiltrating as well as infiltrating tumors. 
Min, and dmin and ring chromosomes 
Patient 28 had some dmin, and patient 31 had many min and dmin chromosomes in the 
specimens. A small ring chromosome was present in the tissue of patient 30. 
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Fig. 1 Fig. 2 
Details of unhanded, C-banded and G-bandcd 
karyotype of patient 22. 
To the left for estimation of the size chromosome 
Al. To the right are two markers: st and m. 
Details of unhanded and C-bandcd karyotype of 
patient 8. 
To the left for comparison of the size chromosome 
Al. To the nght are two markers: sm and m. 
Normal bladder tissue 
Random biopsies from normal bladder tissue in 11 patients with non-infiltrating tumors 
showed neither histopathological nor cytogenetic abnormahties. 
Tumor recurrence and progression 
Of the 18 patients with a stage pTa tumor and recognizable metaphases, 1 (patient 3) had 
the first cytogenetic analysis done in a recurrent tumor, 1 (patient 18) was not treated and 
1 (patient 13) died after 3 months of causes not related to the tumor. Follow up in the 
remaining 15 patients was 12 to 53 months, with a mean of 31 months. None of these 
patients received intravesical chemotherapy before the first recurrence. At least 1 
recurrence was noted in 5 of these 15 patients (table 4), 2 of which had cells with 
chromosomal numbers in the hyperploid range (table 5). In these non-infiltrating 
carcinomas progression occurred only once (patient 17) and the primary tumor showed a 
hyperploid chromosomal range. Patient 1 had a tumor with a normal karyotype and 
suffered 2 recurrences with a small grade 1 tumor. 
Table 4 
Recurrence and progression 
Tumor 
Stage 
pTa 
pTl 
pTl 
Tumor 
Grade 
2 
2 
3 
in the superficial tumors 
Total 
No Patients 
15 
4 
1 
No. Pts. 
with 
Recurrence 
5 
3 
1 
No. Pts. with 
Progression 
Stage 
1 
1 
1 
Grade 
1 
Totals 20 9 3 1 
Of the 8 patients with stage pTl tumors and recogni2able metaphases 3 were not 
évaluable: 1 (patient 25) had nephroureterectomy, 1 (patient 22) died of a myocardial 
infarction and 1 (patient 24) had radiotherapy. Follow up in the remaining 5 patients was 
4 to 49 months (mean 16 months). Four of these patients had a recurrence. Thus, 6 of the 
9 patients with a recurrent tumor had hyperploid cells in the primary tumor. 
The disease progressed in 4 patients with a superficial bladder tumor. All primary tumors 
had cells with chromosomal numbers in the hyperploid range but in 3 the modal number 
was hypodiploid or peridiploid. When the 8 évaluable patients with a primary superficial 
bladder tumor and a hyperploid chromosomal range are considered together, a recurrence 
was noted in 6 (4 with progression). Of the 12 évaluable patients with primary tumors in 
the hypodiploid or peridiploid range, 3 had a recurrence (none with progression). 
Table 5 
Recurrence and progression in relation to cytogenetic data at first examination 
Pt. 
1 
11 
12 
16 
17 
19 
20 
23 
26 
Stage 
Ta(m) 
Ta 
Ta 
Ta(m) 
Ta(m) 
Tl 
Tl 
Tl(m) 
Tl(m) 
Grade 
2 
2 
2 
2 
2 
2 
2 
2 
3 
FoUowup 
(months) 
38 
40 
25 
13 
53 
6 
49 
6 
4 
No. 
recur 
2 
2 
1 
1 
4 
2 
1 
1 
1 
Mo.until 
. first recur. 
16 
7 
17 
6 
10 
2 
3 
4 
2 
Progression 
-
-
-
-
T1/G2 
T1/G3 
plus Ca 
in situ(m) 
-
T2(m)G2 
T3G3 
Chromosome 
range 
46 
36-46 
42-44 
35-71 
38-78 
35-72 
28-73 
46-92 
23-80 
Modal No. 
46 
44 
43 
43/70 
43 
65 
53 
46 
46 
Marker* 
. 
-
-
-
-
submedian, 
median and 
terminal 
subterminal 
-
-
* Unidentifiable structurally abnormal chromosome with the centromere in the submedian, median, 
subterminal or terminal region. 
Mo : Months. 
(m) : Multifocal. 
Discussion 
Cytogenetic analysis of solid tumors is difficult. The most important problem is the 
preparation of a good cell suspension. With bladder tumors the consistency of the tumor 
material appears to be relevant, as well as the amount of tissue available and the 
disaggregation technique used. Genuine papillary tumors that are of soft consistency can 
be worked easily into a cell suspension by mechanical means. However, it is almost 
impossible to make a good suspension by the direct technique with solid material as in our 
study. To reduce the risk of false negative karyotypes a great number of cells must be 
analyzed. However, when only a few chromosomally abnormal cells are found one may 
assume that these cells represent the mahgnant portion of the tissue when 2 or more cells 
show the same abnormalities. Mitoses were seen in most tumors but recognizable 
metaphases were noted in only 45 per cent. Technical improvements in cytogenetic 
studies are especially important for the low grade, low stage bladder cancers, for which 
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new objective criteria of malignant behavior are needed urgently. Near diploid tumors of 
all 3 pathological grades are reported to have a low proliferation rate.6 Relatively more 
mitoses and recognizable metaphases were seen with the direct technique in invasive and 
grade 3 tumors. Nevertheless, mitoses were observed in 64 per cent of the non-invasive 
tumors, which implies, as is our recent experience, that with application of newer 
techniques17"20 and growing experience the percentage of recognizable metaphases, also in 
superficial bladder tumors, will be higher than has been found to date. 
In our study, as in those of others,3"10 non-invasive tumors were mostly hypodiploid or 
diploid. Submucosal invasive tumors showed a wide range of modal numbers. Even 4 of 
the 17 deeper infiltrating tumors had a diploid mode. However, when a distinction is made 
between tumors with cells having chromosomal numbers of 49 or less and those with 
chromosomal numbers greater than 49, there is a difference. All invasive tumors, even if 
only submucosally, showed hyperploid cells. In accordance with previous reports3'4'9 our 
grade 2 tumors showed a wide range in chromosomal mode, as well as in number of 
chromosomes in individual cells. Especially, the invasive grade 2 tumors had a wide range 
in chromosome number. With the criterion of hyperploidy (more than 49 chromosomes in 
cells) all invasive grade 2 tumors had cells with hyperploid numbers. Apparently, the 
range in chromosomal counts is a better reflection of invasion than the modal number. 
The wider the range of the chromosome number the more advanced the tumor is 
biologically. The interpretation would be that the tumors with a wide range of 
chromosomes show a much higher heterogeneity of tumor cells at a more advanced 
biological state than the hypodiploid or diploid tumors, or those with a sharp modal 
number. Therefore, such heterogeneity is reflected in the aggressive behavior of the 
tumor. 
It is well known that invasive and non-invasive lesions occur in the large intermediate 
group of grade 2 tumors.21 The need for tumor markers is greatest in these patients, since 
there also is less correlation between tumor morphology and progression. Studies on 
deoxyribonucleic acid (DNA) analysis have revealed a division that separates the grade 2 
tumors as being 67 per cent diploid and 33 per cent grossly aneuploid.22,23 Of the 74 grade 
2 tumors 48 (65 per cent) were non-invasive and 26 (35 per cent) were infiltrating, as were 
almost all grade 3 tumors (table 1). The finding that non-infiltrating grade 2 tumors nearly 
always are hypodiploid or peridiploid, while infiltrating grade 2 bladder tumors always 
have hyperploid cells supports the idea that there is a distinction within the group of 
intermediate grade bladder tumors, cytogenetically and clinically. 
Nearly all investigators have reported an increasing incidence of markers with increasing 
malignancy. Recurrence and progression rate among non-invasive and superficially 
invasive low grade bladder tumors with markers are reported to be much higher.3'9'24 With 
our routine technique in non-banded preparations we found markers in many hypodiploid 
or near diploid tumors, and in most hyperploid cancers. No difference in the frequency of 
markers according to tumor stage and grade was found. Only 6 tumors were analyzed with 
banding techniques, including 4 of the 18 with marker chromosomes. Possibly, the 
techniques used in our study failed to detect subtle chromosomal abnormalities. The 
submedian marker was seen predominantly in non-invasive tumors. The sub terminal and 
terminal markers occurred only in hyperploid cancers. To date few studies concerning 
banding in bladder tumors without longterm culture have been reported.8'9'25"28 In all of 
these studies only a limited number of tumors were evaluated by banding. Developments 
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in chromosome banding techniques during the last years have indicated that karyotypic 
changes that cannot be established with routine methods often are revealed when the 
chromosomes are analyzed with various banding techniques in cultured cells.17'19 With a 
direct method in cytogenetic analysis of solid tumors, a difficulty encountered especially 
in non-infiltrating tumors was the sparcity of analyzable metaphases. Moreover, the 
chromosomes frequently were fuzzy and contracted, and not suitable for banding. With 
our techniques cells with abnormal chromosomal counts or consitution may have been 
missed. However, long-term (more than 24 hours) culture is a more labor-intensive and 
time-consuming process. Also, it is not certain whether the cells growing in vitro represent 
the spectrum of cells present in the initial suspension. With a modified direct method in 
recent patients,20 we nearly always can see metaphases of good quality, at least suitable for 
C-banding and many times also for G-banding. 
The apphcation of banding techniques allowed the identification of tumor-specific 
chromosomal rearrangements, such as t(9;22) in chronic myeloid leukemia,291(8;14) in 
Burkitt's lymphoma,30 del(13q) in retinoblastoma,31 del(l lp) in Wilms' tumor32,33 and an 
isochromosome of the short arm of chromosome # 12,i(12p), in seminoma and malignant 
teratoma of the testis.3,1·35 In bladder tumors non-random chromosomal changes have been 
demonstrated,19 for instance an isochromosome of the short arm of chromosome # 5, 
monosomy of chromosome # 9 and loss of material from the short arm of chromosome # 
11. This latter condition is of interest in view of the location of the c-Ha-ras oncogene.36 
Only when banding techniques are applied in larger series of bladder tumors with more 
extensive follow up, it will be possible to determine whether specific structural 
chromosomal abnormalities can be used for diagnosis and prognosis in patients with 
bladder cancer. To date chromosomal analyis did not identify unequivocally the earliest 
irreversible changes predicting invasion and metastasis. Just as in light microscopy, 
electron microscopy37 and the use of biochemical markers, such as ABH antigen deletion,5 
chromosomal analysis can identify only specific risk factors regarding the future behavior 
of bladder tumors. When present, these risk factors should be used together. 
Nuclear DNA measurements have shown a correlation between the degree of ploidy and 
the degree of malignancy .22'23 A general similarity between the results of chromosome and 
DNA analysis is reported.10 However, DNA analysis cannot distinguish between diploid 
and near diploid tumors,10 it cannot distinguish individual cells and it cannot establish 
specific morphological chromosomal abnormalities, which may recommend that 
cytogenetic examination should not be replaced by flowcytometry. 
We conclude that the range in chromosomal counts appears to be a better reflection of 
invasion than the modal number. Noninvasive grade 2 tumors are mostly hypodiploid or 
diploid. Cytogenetically, there seems to be no difference between the invasive grade 2 and 
grade 3 tumors. During the limited follow up, recurrence was noted in hypodiploid, 
peridiploid and hyperploid tumors. Progression possibly is limited to tumors with 
hyperploid chromosomal numbers. Such tumors appeared to be more advanced 
biologically, even if they had a near diploid modal number. Application of new cytogenetic 
techniques, especially the advanced banding techniques, and evaluation during a longer 
follow up are needed to obtain more information about the prognostic meaning of marker 
chromosomes. 
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Grading in superficial bladder cancer 
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Summary 
In a prospective study on grading of superficial papillary neoplasms of the bladder a 
distinction was made in tumors showing only increased cellularity without appreciable 
cellular and nuclear deviation (called grade 1), tumors showing slight cellular variation 
(grade 2a) and tumors showing clear cytologic deviation and a tendency to loose normal 
polarity (grade 2b). A total of 91 patients with a superficial tumor was évaluable for follow 
up (mean 24 months). Grade 2a tumors appeared to recur much later and in fewer patients 
than grade 2b tumours. Progression was seen in 4% of grade 2a tumors and in 33% of grade 
2b carcinomas. Adapting our results to the W.H.O.-grading system we propose to classify 
as low grade all tumors in this study defined as grade 1 and 2a, and as intermediate grade 
tumors in this study defined as grade 2b. 
Introduction 
In the majority of patients with a first diagnosis of bladder cancer, the tumor shows no 
invasion or only invasion of the lamina propria (Cutler et al., 1982). Once diagnosed, 
progression and recurrence rate of these superficial tumors are found to be associated with 
different histopathological parameters, such as depth of invasion, grade, papillary or 
nonpapillary growth (Koss, 1975; Kern, 1984), number and size of visible tumors (Heney 
et al., 198 3 ; Lutzeyer et al., 1982) and the presence of moderate to severe dysplasia in non-
tumor bearing areas of the bladder (Althausen et al., 1976; Cutler et al., 1982). For 
prediction of the prognosis newer approaches such as deletion of blood group isoantigens 
(Summers et al., 1983), cytogenetic studies (Sandberg, 1977; Summers et al., 1983), DNA 
and RNA histograms (Devonec et al., 1981) and morphometric studies (Ooms et al., 1983) 
are available. Nevertheless, cytohistological grade is often the most important single item 
of prognostic value. 
Several grading systems have been described (Broders, 1922; Bergkvist et al., 1965; 
Mostofietal., 1973;Pugh, 1973;Koss, 1975; Friedelletal., 1976). They differ especially 
in the definition of grade 1 papillary lesions, and the variable interpretation of grade 2 
neoplasms. 
To analyse the prognostic significance of the different histopathological criteria, in this 
study the group of so called intermediate grade tumors were separated in two subgroups. 
The grading criteria used were correlated to tumor stage, recurrence rate and progression. 
Patients and methods 
Between 1980 and 1986 168 patients with a newly diagnosed transitional cell carcinoma 
(T.C.C.) of the urinary bladder were studied (see table 1). Patients were assessed 
according to the requirements of the T.N.M.-system (Harmer, 1978). At initial 
presentation urine was collected for cytologic examination, and biopsies were taken of the 
tumor and any suspected area, and of preselected areas with normal looking urothehum, 
distant form the tumor (lateral to each ureteral orifice and in the midline posteriorly). 
From every tumor multiple slides were graded by two pathologists, making one final 
classification. When more than one grade or stage was seen in tumor specimens of the same 
patient, or infiltration was doubtful, the tumor was classified according to the highest 
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Fig. 1 Grade 1 papillary urothelial tumor. Slightly irregularly thickened epithelium. No appreciable cellular 
pleomorphism. 
(HE 250x). 
•mW? 
Fig. 2 Grade 2a papillary urothelial tumor. Slightly irregularly thickened epithelium with some cellular and 
nuclear deviations. 
Normal polarity of nuclei. (HE 250x). 
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Fig. 3 Grade 2b papillary tumor. Irregularly thickened epithelium with loss of normal polarity of nuclei. 
Moderate abnormalities of cells and nuclei. (HE 250x). 
.
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Fig. 4 Grade 3 papillary urothelial tumor. Irregularly thickened epithelium with total disarrangement of nuclei 
Severe pleomorphism of cells and nuclei. (HE 250x). 
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grade and stage. If suspicious or mahgnant cells were found in the urine, cytology was 
considered positive. Pathological parameters at the time of the initial diagnosis were 
correlated with the clinical course in 122 patients with a superficial (Ta or Τ1 ) tumor, only 
treated by TUR and followed for 3 to 60 - mean 24 - months. 
If chemotherapy, immunotherapy or radiotherapy was applied, or tumor progression was 
diagnosed, follow up ended. 
The recurrence rate was defined as the total number of cystoscopies at which recurrences 
were observed and microscopically proven, divided by the sum of months of follow up till 
the last cystoscopy, multiplied by 100. For tumor progression, subseqent deeper invasion 
was taken as criterion. Statistical analyses were done with the chi-square test. 
Grading system 
Grade 1 (fig. 1) was applied to tumors, covered by slightly and irregularly thickened 
transitional epithelium which showed no appreciable cellular deviation (Bergkvist et al., 
1965; Koss, 1975). Tumors covered by irregularly thickened transitional epithelium with 
slight cellular deviation and some variation in size of cells and nuclei were called grade 2a. 
Normal polarity of individual cells was seen here (fig. 2). In grade 2b tumors, (fig. 3) the 
epithelium was thickened and displayed distinct cellular irregularity with clear variation 
in nuclear and cellular size. Hyperchromasia was quite noticable. There was a tendency to 
loose the normal polarity of individual cells. Grade 3 tumors (fig. 4) were characterized by 
considerable cellular deviation with strong variation in size and shape of cells and nuclei. 
Individual cells and epithelial cords were disarranged. Locally there could be complete 
loss of transitional epithelial characteristics. 
The inter- and intra-observer variability in grading was tested at the end of the study. 
Randomly chosen slides from 20 patients were separately seen at two occasions by two 
pathologists. In a last common session the slides were reevaluated to make one final 
classification. 
Results 
Tumor stage and grade 
Tumors classified as grade 1 were never invasive (see table 1). Grade 2a carcinomas 
appeared mostly noninvasive, grade 2b in the majority submucosally or deeply invasive 
(p=0.001). Grade 3 tumors were significantly deeper infiltrating than the grade 2b cases 
(p=0.004). 
Of 89 new cases with a superficial tumor where selected mucosal biopsies of normal 
looking urothelium were examined, only in 4 severe dysplasia was shown (see table 2). In 
3 of these cases this regarded patients with a multifocal T l tumor. No correlation was 
demonstrable between the occurrence of slight dysplasia in the selected mucosal biopsies, 
and the clinical course. 
Cytology of prae-cystoscopy urine was positive in 13 of 57 cases with a grade 2a tumor 
(23%), in 26 out of 40 cases with a superficial grade 2b tumor (65%). 
Clinical course of superficial (pTa - pTi) tumours 
91 Patients with a superficial tumor were évaluable for follow up, from 3 to 60 (mean 24) 
months (see table 3). The clinical behavior of grade 1 tumors was not significantly 
different from grade 2a carcinomas. Of the 54 évaluable grade 2a patients, 42 (78%) 
remained disease-free, compared with only 9 (43%) of the 21 grade 2b tumors (p = 0.008) 
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Table 1 
Correlation between tumor stage and grade 
Grade 
1 
2a 
2b 
3 
Totals 
Ta 
13 
54 
14 
-
8i 
T l 
-
3 
30 
8 
41 
T2 
-
-
5 
11 
16 
T3 
-
-
9 
15 
24 
Stage 
T4 
-
-
1 
3 
4 
TisCm) 
-
-
-
2 
2 
Totals 
13 
57 
59 
39 
168 
sTis(m): Carcinoma in situ on multiple places. 
Table 2 
Histology of selected mucosal biopsies of normal looking urothelium in new cases with superficial tumors 
Grade 
Gl 
G2a 
G2b 
G3 
Totals 
No. 
of 
Patients 
9 
45 
31 
4 
89 
Histological 
Normal 
8 
38 
26 
3 
75 
appearance 
Hyperplasia 
0 
0 
0 
1* 
I 
Mild 
Dysplasia 
1 
7 
2 
0 
IO 
Severe 
Dysplasia 
0 
0 
3 
1* 
4 
Carcinoma 
0 
0 
0 
0 
0 
* Both in the same patient. 
Table 3 
Relation of tumor grade and stage with clinical course for the superficial tumors 
η patients évaluable 
η patient disease free 
recurrence rate 
tumour progression 
1 
12 
8(67%) 
2.3 
1(8%) 
2a 
54 
42(78%) 
1.5 
2(4%) 
Grade 
2b 
21 
9(43%) 
3.1 
7(33%) 
3 
4 
2(50%) 
4.3 
1(25%) 
Ta 
71 
50(70%) 
2.1 
4(6%) 
Stage 
Tl 
20 
11(55%) 
3.0 
6(30%) 
Follow up 3 to 60 - mean 24 - months 
Table 4 
Recurrence probabilities 
(Kaplan-Meier method) 
Stage-Grade Years of follow up 
1 2 3 
TaG2a 
TaG2b 
TlG2b 
0.05 
0.31 
0.49 
0.13 
0.65 
_* 
0.43 
0.83 
-* 
-* Not évaluable because of chemotherapy or tumor progression. 
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There is a clear difference in recurrence rate between grade 2a and grade 2b tumors, 
respectively 1.5 and 3.1. The observed 1 -year recurrence probabihties were 5,31 and 49 
per cent, respectively, for TaG2a, TaG2b and TlG2b tumors (see table 4). These 
probabilities increased after three years to 43 per cent for TaG2a tumors, 83 per cent for 
TaG2b. 
Tumor progression was seen in 2 of the 54 grade 2a tumors (4%). Both being Ta at first 
diagnosis, recurred as a T l tumor, one after 13 months, the second after 53 months. Of 
the 21 grade 2b carcinomas 7 showed tumor progression (33%): 2 out of 8 TaG2b tumors, 
5 out of 13 TlG2b tumors. 
Five recurred as deeply infiltrating bladder cancers, four of which half a year after the 
initial diagnosis. So progression was significantly more frequently seen with grade 2b than 
with grade 2a tumors (p = 0.002). 
Multiple tumors were seen in 2 of the 12 évaluable patients with a grade 1 lesion (17%), 10 
of 54 with a grade 2a ( 18%), and 4 of the 21(19%) with a grade 2b carcinoma. Multiplicity 
could not be seen as an explanation for the difference in clinical behavior between grade 1 
- 2a, and grade 2b tumors. 
Table 5 
Inter- and intra-observer variability in grading 
Case number 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
Original 
Classification 
1 
1 
1 
2a 
2a 
2a 
2a 
2a 
2a 
2b 
2b 
2b 
2b 
2b 
2b 
2b 
3 
3 
3 
3 
Testing Session 
Pathologist I 
1 
2a 
2a 
2a 
2a 
2a 
2a 
2b 
2b 
2b 
3 
3 
2b 
3 
3 
3 
2b 
3 
3 
3 
3 
2 
2a 
2a 
2b 
2b 
2a 
2a 
2a 
2b 
2b 
3 
2b 
3 
3 
3 
3 
2b 
3 
3 
3 
3 
Pathologist II 
1 
2a 
2a 
2a 
2b 
2a 
1 
2a 
2b 
2b 
3 
3 
2b 
2b 
3 
2b 
2b 
2b 
3 
3 
3 
2 
2a 
2a 
2a 
2b 
2a 
2a 
2a 
2b 
2b 
3 
2b 
2b 
2b 
3 
3 
2b 
2b 
3 
3 
3 
Final 
classification 
Pathologist I+ 11 
2a 
2a 
2a 
2b 
2a 
2a 
2a 
2b 
2b 
3 
3 
2b 
2b 
3 
3 
2b 
2b 
3 
3 
3 
Inter- and intra-observer variability in grading 
Three cases, originally classified as grade 1, finally were graded 2a (see table 5). In four 
cases the original classification was grade 2b, the final grade 3. So fairly often the 
distinction made between grade 1 and grade 2a tumors respectively between grade 2b and 
grade 3 tumors appeared not consistent. Of more importance is that three cases originally 
graded 2a, finally were graded 2b. Common practice in our clinic is, when a tumor 
recurrence or metastasis is diagnosed, to reexamine in a common session from pathologists 
and urologists all slides from preceding tumors, comparing the tumor grade formerly 
given with the then known clinical behavior and eventual additional parameters. With 
respect to the distinction between grade 2a and 2b tumors, much less discrepancy was seen 
between the testing sessions at the end of the study. 
Discussion 
Difficulties in the comparison of grading in publications on bladder tumors exist 
especially in superficial papillary tumors. For some pathologists a grade 1 papillary lesion 
shows only thickened urothelium without significant nuclear abnormalities (Bergkvist et 
al., 1965; Koss, 1975). For others grade 1 applies to tumors that have the "least degree of 
cellular anaplasia compatible with a diagnosis of malignancy" (Mostofi et al., 1973) or 
nuclear pleomorphism and disturbance of cellular architecture (Friedell et al., 1976). 
Even when the same grading system is used, there appears to be a disturbingly high intra-
and interindividual inconsistency in tumor grading (Ooms et al., 1983). Aim of this study 
was the search for a sharper histological distinction between low and intermediate grade 
urothelial cell carcinomas based on the clinical behavior of these tumors. 
Almost all grade 1 and grade 2a tumors appeared to be stage Ta. There was a close 
correlation between grade 2b and infiltration. Clinical behavior of TaG2b tumors 
appeared worse than for TaG2a tumors. Therefore grading is on its own of prognostic 
value apart from tumor stage. 
We found a striking association between tumor grade and positive urine cytology, like is 
reported before (Heney et al., 1983). In patients with newly diagnosed noninfiltrating (Ta) 
tumors, abnormalities in selected mucosal biopsies were seldom found, mostly only slight, 
and if so, the clinical course was not significantly different from those with normal 
mucosal biopsies, as is shown before (Heney et al., 1983). We agree with Wallace and 
associates that there is no good case for routine mucosal biopsies in such patients on first 
presentation (Wallace et al., 1979). 
With regard to recurrences and progression, we did not find a significant difference 
between grade 1 and grade 2a tumors. There was however a very significant difference in 
recurrence probability and the rate at which tumors recurred between Ta grade 2a and 2b 
tumors, after one year 5 and 31 per cent respectively. Similarly striking was the difference 
in tumor progression between grade 2a and grade 2b tumors, 4 and 33 per cent 
respectively, occurring late with grade 2a carcinomas, fairly early with grade 2b lesions. 
These findings are in accordance with the conclusions of others that with increasing tumor 
grade time intervals from presentation to recurrence and progression become shorter 
(England et al., 1981; Cutler et al., 1982). 
In our study too there was some inconsistency in grading between the two pathologists at 
various testing sessions. There were however only minor differences in grading between 
the testing sessions at the end of the study, and the final common classification. 
36 
Apparently through the years our pathologists learned to handle the grading criteria used. 
Because of the importance of histopathological grading a continuing study is necessary, 
ever again comparing the primary slides of first diagnosis with biopsy specimens from 
recurrences. 
With respect to recurrences and progression according to tumor stage this series appeared 
to be in accordance with other studies (Greene et al., 1973; England et al., 1981 ; Cutler et 
al., 1982). Eight per cent of our cases were classified as being grade 1. This low percentage 
is due to the strict adherence to the grading criteria used. Pooling our 13 grade 1 and 57 
grade 2a tumors in one group, the percentage for low grade tumors in our material is 42, 
more in accordance with the percentage of low grade tumors in other series, varying 
between 23 per cent (Friedell et al., 1976) till 35 per cent (Cutler et al., 1982). 
Mostofi (1975) stated: basically there are two categories of bladder tumors, grade I and 
grade III. As we demonstrated in our prospective study the intermediate category can 
indeed be separated in two groups on cytohistological and clinical grounds: one, grade 2a, 
belonging to grade 1; the other, grade 2b, resembling grade 3. We found a difference 
between grade 2a and grade 2b tumors with respect to chromosomal numbers (Pauwels et 
al., 1987; this thesis chapter IV). Clearly grade 1 tumors in the W.H.O.-grading system 
ought to be defined as our grade 1 and grade 2a tumors. 
It is obvious that classifying superficial bladder tumors in two groups with a rather distinct 
prognosis has far going consequences regarding mode of follow up and the application of 
prophylactic chemotherapy. For patients with a solitary noninfiltrating low grade tumor 
the first cystoscopic control could be postponed till at least half a year after the initial 
diagnosis. Application of intravesical chemotherapy could be reserved for those patients 
showing multifocal disease, or recurrences, and should be done with those tumors 
showing histological clear or strong deviations, our grade 2b and grade 3 lesions. 
In summary we conclude that the interpretation of the W.H.O.grading classification 
should be that in papillary urothelial cell carcinomas of the bladder those tumors should 
be called low grade which show irregularly thickened epithelium with or without slight 
nuclear and cellular deviations, but with normal polarity of individual cells, in this study 
called grade 1 and grade 2a. The classification grade 2 should be given to tumors defined 
by us as grade 2b. Grade 3 applies to tumors with the most severe degree of cellular 
anaplasia. 
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Summary 
Cytogenetic analysis was performed in 92 newly diagnosed transitional cell bladder 
carcinomas. The results of this analysis were correlated with the clinical course in the 
superficial tumors. Low grade tumors appeared to have hypo- or peridiploid chromosomal 
numbers. Intermediate grade tumors were characterized by chromosomal counts up to 
the hyperdiploid range, but could have a peridiploid modal number. With respect to the 
clinical course of superficial tumors the range in chromosomal counts appeared to be more 
reliable than the modal number. The significant difference in chromosome numbers 
between low, intermediate and high grade tumors may be considered as a biological basis 
for grading. 
Introduction 
The natural history of a papillary tumor of the bladder is unpredictable. Next to tumor 
stage, grade is at present the most important indicator of the clinical behavior of a bladder 
tumor (Kern, 1984). However, reports regarding grade are not always completely 
comparable because different grading systems are used, or different interpretations are 
given to one grading system (Hofstädter et al., 1984). Chromosomal analysis is mentioned 
as one of the more objective criteria of the malignant potential of bladder cancer (Lamb, 
1967; Spooner and Cooper, 1972). 
Cytogenetic studies showed a positive correlation between histological grade and modal 
chromosome numbers for low and high grade bladder tumors (Spooner and Cooper, 1972; 
Wijkström et al., 1984). In intermediate grade tumors normal as well as abnormal modal 
numbers were found. In another study (Pauwels et al., 1987; this theses chapter III) an 
interpretation of the W.H.O. grading criteria was established which appeared to correlate 
with rate of recurrences and tumor progression. 
The aim of this study was to investigate whether this interpretation of the W.H.O. grading 
classification could be confirmed by a cytogenetic study. 
Patients and methods 
Between 1980 and 1986, from 92 patients with a primary transitional cell carcinoma of the 
bladder only treated by TUR,chromosomal data from tumor specimens were achieved 
(see table 1). 
Table 1. 
Number of patients in relation to tumor stage and grade. 
Grade Tumor stage Totals 
Ta T l T2-4 
Gl 31 1 - 32 
G2 9 15 11 35 
G3 - 5 20 25 
Total 40 21 31 92 
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Staging was done according to the T.N.M.-system (Harmer, 1978). As grade 1 were 
classified tumors showing increased cellularity with or without slight nuclear and cellular 
variations but with normal polarity of individual cells. Tumors showing clear cytological 
deviations with a tendency to loose normal polarity were classified grade 2. Tumors were 
called grade 3 if considerable cellular deviation was seen, with strong variations in size and 
shape of cells and nuclei and a loss of normal cellular architecture. 
Patients with a superficial (Ta-Tl) low or intermediate grade tumor were followed by 
cystoscopy for 3 to 62 - mean 28 - months. If chemotherapy, immunotherapy or radical 
therapy was applied, or tumor progression occurred, follow-up ended. 
Cytogenetic analysis. 
For microscopic analysis of chromosomes, cells in metaphase were obtained from a 
suspension of single cells. After colcemid arrest, hypotonic treatment and fixation, the 
chromosomes were routinely stained with Giemsa. For further identification of 
chromosomes, specific banding techniques are available. The techniques used for 
cytogenetic analysis -direct method or short term culture - have been described previously 
(Smeetsetal.,1985). 
Analysable metaphases, at least 5 (average 28) per case were photographed and karyotyped 
according to the Paris nomenclature (I.S.C.N., 1978). The tumors were classified 
according to the modal chromosome number and chromosome range. The latter 
classification distinguished the tumors with cells only in the hypodiploid or peridiploid 
range (49 or less) and cells with more than 49 chromosomes (hyperdiploid). 
Marker chromosomes, structurally abnormal chromosomes, as mentioned in this study 
were shown by routine techniques, mostly in non-banded preparations. 
Results 
Normal bladder tissue. 
In 15 patients with non-infiltrating tumors, random biopsies from cystoscopically normal 
bladder tissue showed neither histopathological nor cytogenetic abnormalities. 
Tumor stage and grade. 
The majority of non-invasive tumors (Ta) had peridiploid chromosomal numbers 
(see table 2). 
Table 2. 
Tumor stage in relation to chromosomal numbers. 
chromosomal number Number and stage of tumors 
Ta Tl T2-4 
modal number ^ 49 35 9 6 
modal number > 49 5 12 25 
range S 49 31 - -
range >49 9 21 31 
In all infiltrating tumors, cells with more than 49 chromosomes were present, although 
the modal number often was peridiploid. The difference in the range of chromosomal 
numbers between non-invasive and invasive tumors is significant (p < 0.001). 
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As is shown in table 3 all except one grade 1 tumors had a modal number of 49 or less. In 
nearly half of the 35 grade 2 tumors the modal number was peridiploid. Nearly always, 
however, cells in the hyperdiploid range were seen like in all grade 3 tumors. The 
differences in chromosomal numbers (mode and range) between grade 1 and grade 2 
tumors are significant (p < 0.001). Between grade 2 and grade 3 tumors there was a 
significant difference in modal number (p < 0.002). 
Table 3. 
Tumor grade in relation to chromosomal numbers. 
Chromosomal number 
modal number S 49 
modal number > 49 
range ^ 49 
range > 49 
Gl 
31 
1 
28 
4 
Number and grade 
G2 
17 
18 
3 
32 
of tumors 
G3 
2 
23 
25 
Marker chromosomes (see fig. 1) were found in 17 of the 40 non-invasive tumors (43%) 
and in 31 of the 52 invasive cases (60%) (p = 0.22). Nine out of 32 grade 1 tumors showed 
markers (28%) compared with 39 of the 60 grade 2 and grade 3 cases (65%). So, in higher 
grade tumors more often marker chromosomes were found (p = 0.003). 
Follow up of superficial low and intermediate grade tumors. 
Fourty-two patients with a superficial low or intermediate grade tumor were évaluable for 
follow up (see table 4). 
Table 4. 
Correlation of results of chromosomal analysis with clinical course for superficial (Ta - Τι) low and 
intermediate grade bladder tumors. 
patients 
évaluable 
disease free 
with tumor 
progression 
recurrence rate 
modal numbei 
S 49 
37 
19 (51%) 
7 (19%) 
3.0 
>49 
5 
0" 
2 (40%)d 
2.7 
Results of chro 
chromosomal 
« 4 9 
28 
16 (57%) 
3 (11%) 
2.9 
mosomal anal; 
range 
>49 
14 
3 (21%)b 
6 (43%)e 
3.0 
psis. 
marker chromosomes 
no yes 
24 
13 (54%) 
4 (17%) 
2.2 
18 
6 (33%)c 
5 (28%/ 
3.9 
Follow up 3 to 62 - mean 28 - months. 
Recurrence rate: η recurrences/n months patient follow up χ 100 
'ρ = 0.07; ь р = 0.16; 'ρ = 0.50; d p = 0.62; 
'ρ = 0.05; 'ρ = 0.63 
Fifty-one percent of the tumors with a peridiploid modal number did not recur. In the 
group with hyperdiploid modal numbers all tumors recurred (p = 0.07). With respect to 
tumor progression no significant difference was seen between these two groups (p = 0.62). 
If, however, in a tumor chromosomal numbers in the hyperdiploid range were shown, 
tumor progression was seen significantly more often than in the group with lower 
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chromosomal numbers (ρ = 0.05). 
The tumor recurrence rates showed no significant differences between the groups. 
However, estimations using the Kaplan-Meier method show that in the group with a 
hypo- or peridiploid chromosomal range the first 18 months only 10% had a recurrence, 
which figure rose to 69% after 42 months. In the group with a hyperdiploid chromosomal 
range, 54% had at least one recurrence after 18 months. So, tumors with a hypo- or peri­
diploid chromosomal range clearly recurred much later. 
In four cases progression was seen in tumors with near normal modal numbers but a 
hyperdiploid chromosomal range. With respect to the clinical course, no significant 
difference between the groups with or without marker chromosomes was observed. 
An addendum shows the histopathological and cytogenetic data, and follow-up of the 
clinical course for each patient. 
Discussion 
In a previous study about grading in superficial bladder cancer, a clear correlation between 
morphological criteria and the clinical course of bladder tumors was found (Pauwels et al., 
1987). The present study was done to see whether a correlation between chromosomal 
abnormalities and the grading criteria used could be demonstrated. 
Grade 1 tumors appeared to have hypo- or peridiploid chromosomal numbers. Grade 2 
tumors show in half of the cases a peridiploid modal number but nearly always they 
contain a number of cells with more than 49 chromosomes. In grade 3 tumors the 
chromosomal mode is strongly hyperdiploid. Other authors also reported that grade 2 
tumors are heterogeneous with respect to modal number (Spooner and Cooper, 1972; 
Wijkström et al., 1984). The significant difference in chromosomal range between grade 
1 and grade 2 tumors is not reported before. 
Tumors graded by us as intermediate recur significantly earlier, and progress more often 
than low grade tumors (Pauwels et al., 1987). These grade 2 tumors appear to have 
chromosomal numbers up to the hyperdiploid range. This means that nuclear 
pleomorphism, enlargement and hyperchromasia probably reflect the increase in 
chromosome number and the increased aggressiveness of a tumor. 
Tumors having a peridiploid modal number but a range till in the hyperdiploid region, 
tended to behave worse than tumors with only near normal chromosomal numbers. The 
finding of hyperdiploid modal numbers in intermediate grade superficial bladder tumors, 
like by FCM analysis higher DNA values, is a bad prognostic sign (Wijkström et al., 
1984). However, a near normal modal chromosomal number does not always indicate a 
benign behavior of the tumor. 
Marker chromosomes in superficial bladder cancers were regarded as a very bad 
prognostic factor (Falor and Ward, 1978; Summers et al., 1981). In our study this could 
not be confirmed. For establishing structural abnormaUties so called chromosome 
banding techniques are necessary. 
By the use of different banding techniques non-random chromosomal changes have been 
demonstrated in bladder tumors (Gibas et al., 1984; Atkin and Baker, 1985). The 
prognostic significance of the different changes are not yet known. The increasing 
variation in chromosomal number during the progression of the neoplasia is believed to 
confer proliferative advantage to the tumor cells (Yunis, 1983). 
Our grading criteria in superficial bladder cancer were proved to have a clinical basis with 
43 
respect to tumor stage, rate of recurrences and tumor progression (Pauwels et al., 1987). 
The conclusion of this study may be that with chromosomal analysis we were able to give 
a biological meaning to our grading system. 
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Fig. 1 A G-banded karyotype of a Ta Tumor. 
The abnormal chromosomes are indicated by arrows; "a" has a deletion of the long arm (9 q-); "b" is an 
unrecognizable chromosome (marker chromosome). 
(Giemsa, χ 4000). 
45 
Addendum: 
Histopathologic and cytogenetic data for the initial biopsy from individual bladder carcinoma patients with 
follow up. 
Patient 
Case 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
Age 
66 
51 
27 
63 
64 
65 
66 
72 
70 
58 
57 
41 
59 
63 
73 
55 
17 
77 
56 
60 
58 
91 
65 
56 
71 
61 
63 
60 
76 
48 
66 
65 
73 
82 
61 
72 
66 
78 
44 
83 
55 
78 
66 
77 
86 
59 
72 
Sex 
M 
M 
M 
M 
M 
M 
M 
F 
M 
F 
M 
M 
M 
M 
M 
M 
M 
M 
M 
F 
M 
M 
M 
M 
M 
M 
M 
M 
M 
M 
M 
M 
M 
M 
M 
F 
M 
M 
M 
M 
M 
F 
M 
M 
M 
M 
M 
Tumor 
Τ 
a(m) 
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Abstract 
Chromosome analysis using G- and C-banding was performed in thirteen primary 
transitional cell carcinomas of the bladder. The chromosome preparations were obtained 
by a direct method. In eight tumors with a (near) diploid modal chromosome number the 
most frequently observed chromosome aberrations were: (partial) monosomy 
chromosome # 9 in four cases, deletion of chromosome # lOq in two cases and partial 
trisomy of chromosome # 1 in two cases. 
In five tumors with a modal chromosome number in the triploid or tetraploid range the 
chromosomes # 1 , # 3 , # 7 , # 9 , # 1 1 and # 1 7 were numerically and or structurally 
abnormal in at least four cases. In three out often males, the Y-chromosome was missing. 
These findings suggest that the loss of chromosome # 9, and possible also loss of lOq is a 
primary event in the karyotypic evolution of transitional cell carcinoma of the bladder. 
Introduction 
Chromosome analysis of transitional cell carcinoma (TCC) of the urinary bladder has 
revealed the involvement of a number of chromosomes. In one study, the presence of an 
isochromosome i(5p), an isochromosome i(8q), deletion and translocation of chromosome 
# 8, monosomy # 9 and interstitial deletion of # 13 were noticed [1]. 
Another study reported the involvement of chromosomes # 1 and # 1 1 and to a lesser 
degree chromosomes # 3 and # 17 [2]. Also alterations of chromosomes # 6, and # 13 
have been published as non-random abnormalities [3]. Recently deletions of 10q24 and 
21q22, trisomy # 7 and aberrations of # 9, # 13, # 15 and # 20 were added to the list of 
alterations [4]. 
Hitherto, some dozens of cases are described with successful banding of the tumor 
chromosomes 
After the introduction of a new technique in our laboratory, G-banded chromosomes 
could be obtained much more frequently during the past [5]. In this report the 
chromosomal findings of 9 cases, studied with this method, are combined with the results 
of four patients studied at an earlier date. 
Materials and methods 
The tumor samples were collected and transported in 0.5% sodium citrate -I- 0.5 μg 
colcemid/ml and prepared as described elsewhere [5]. 
All tumors were primary tumors. None of the patients, before first resection, received 
chemotherapy or radiation therapy. Two of them recurred. Further data on the 13 cases 
are shown in Table 1. 
Clinical staging of the tumors was done according to the rules of the Union International 
Contre le Cancer [6] and grading according to the WHO system [7]. In addition, 
intermediate tumors were divided in G2a and G2b. The latter is less differentiated than 
the former [8]. 
In addition to the cells with G- and C-banded chromosomes, a number of unbanded 
metaphases could be analyzed. Therefore the chromosomes of at least 15 metaphases of 
every tumor were counted in order to increase the reliability of the chromosome number. 
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Results 
The tumors fell into two groups: those with near diploid modal chromosome numbers 
(cases 1-8) and those with near tri- or tetraploid modal numbers. 
Case 1.: Mode 46. Range 43-90. 
Two G-banded and two C-banded metaphases with 46 chromosomes were 
analyzed. A lOq- [del(10)(q22)] was present. There were some (near) tetraploid 
cells, which were unsuitable for chromosomal analysis. 
The modal karyotype was: 46,XY, del(10)(q22). 
Case 2.: Mode 46. 
All cells counted showed 46 chromosomes. 
Two G-banded and two C-banded metaphases were analyzed. One 
chromosome # 9 showed a deletion of the long arm 9q-[del(9)(q22?)]. One 
chromosome # 12 was missing and one marker chromosome, probably derived 
from a chromosome # 1 2 , was present. 
The modal karyotype was: 46, XY, 9q-, -12, + mar. 
Case 3.: Mode 45. Range44-45. 
Five G-banded and two C-banded metaphases were analyzed. Consistent 
features were monosomy # 9 and 10q-[del(10)(q22)]. 
The modal karyotype was: 45,XY, -9, del(10)(q22). 
Case 4.: Mode 47. 
All cells, except one, had 47 chromosomes. 
Seven G-banded and two C-banded metaphases were analyzed. Consistent 
features were 2q-, 9q+, +i(8q). Furthermore, the short arm of one 
chromosome # 8 was probably abnormal. 
The single diploid cell showed no karyotypic abnormalities. 
The modal karyotype was: 47,XY, 2q-, +i(8q), 9q+. 
Case 5.: Mode 46. Range 42-46. 
Seven G-banded and two C-banded metaphases were analyzed. Consistent 
features were an extra chromosome lp-[del(l)(p22)] and a missing Y-
chromosome. 
The modal karyotype was: 46,X, -Y, + lp-. 
Case 6.: Mode 44. Range 41-72. 
Three G-banded and two C-banded metaphases were analyzed. Missing were 
one copy o f # 9 , # 11,# 14 and the Y-chromosome. 
Two structurally abnormal chromosomes were present: lp-[probably 
del(l)(pl3)] and an 1 Ip-H chromosome. 
There were some (near) triploid cells, which were unsuitable for chromosomal 
analysis. 
One diploid cell showed no karyotypic abnormalities. 
Eleven months after the first resection a biopsy specimen of a recurrent tumor 
was obtained which showed the same modal karyotype. 
The modal karyotype of both resections was: 44,X,-Y, +lp-,-9, Ι Ι ρ + , - Η . 
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Case 7.: Mode 47. Range 44-86. 
Three G-banded and two C-banded metaphases were analyzed. In all cells 
examined trisomy # 20 was present. 
Six months after the first resection, a biopsy specimen of a recurrent tumor at 
the primary site was obtained which showed the same karyotype. 
There were a few near tetraploid cells, which were unsuitable for chromosomal 
analysis. 
The modal karyotype of both resections was: 47,XY, + 20. 
Case 8.: Mode 42. Range 41-86. 
Ten G-banded and two C-banded metaphases were analyzed. Missing 
chromosomes were one copy of # 3, # 6, # 7, # 17, one X-chromosome and 
both copies of # 9. A dicentric translocation, tdic (7;9)(pl 1 ;pl l)[7qter—»pi 1 : : 
9pl 1—»qter] and two marker chromosomes were present. Mar 1, a large 
marker, was composed of most of a chromosome # 3 and the short arm 
(including the centromere) of # 6. Between these parts a homogeneously 
staining region (HSR) was present. With C-banding the presence of the two 
centromeres was demonstrated. The composition of this marker is probably: 
3qter—»pl3;HSR;6ql3—»ptcr. Mar 2 is a derivative 9 chromosome and is 
probably a t(9;17)(q34;q21?) [9pter^· q34:: 17q21? -+ qter?]. 
A cell with 57 chromosomes was also fully karyotyped. The HSR containing 
marker and two of the dicentric translocation chromosomes as described were 
present. Besides, a small metacentric marker chromosome was seen. 
In the metaphases with about 85 chromosomes, present in 8 out of 60 cells, two 
HSR containing markers were present. Further karyotyping was impossible. 
The modal karyotype was: 42,X, -X, -3, -6, -7, -9, -9, + t(7;9), -17, + mar 1, 
+ mar 2. 
Case 9.: Mode 60. Range 52-63. 
Six G-banded and two C-banded metaphases were analyzed. Consistent 
features were: a translocation t(l;6Xpl2;pl2) [6pter—>pl2::lpl2 —>lqter], 
del 2(ql2), 4p+, del 9(ql3), l l p + , 12p-(-, two abnormal derivative 13 and 14 
chromosomes, 17q-l-, 19q-l-,20q-l- and three different markers. Chromosomes 
# 1, # 3, # 7, and # 17 were present in triplicate. Chromosomes # 2, # 10, # 
12, # 14, were present in single copies. No normal # 1 3 and # 14 were seen. 
Themodalkaryotypewasmostprobably:60,XY,+X, + 1, + t(l;6)(pl2;pl2), 
2q-, +3 , +4q+, +7, +9q-, -10, -l-llp+, 12p+, 13p+, 13p+, 14p-l-, 14p+, 
+ 17, +17q-l-, +19q+, +20q+, + mar 1, + mar2, + mar3. 
Case 10.: Mode 83. Range 64-85. 
Four G-banded and two C-banded metaphases were analyzed. Consistent 
features were 5 structurally abnormal chromosomes, three of which could be 
identified to some extent: 12q+,6q-,21p+?. The remaining two were 
qualified as markers. 
Therefore, the modal karyotype was most probably: 83,XX,+X, + 1, +2, +3 , 
+3 , +4, +5 , +6, +6q-, +7, +8, +8, +9, +10,-1-10, +11, + 11, +12, 
+ 12q+, +13, +14, +15, +16, +17, +17, +18, +19, +19, +20, +20, +21, 
+ 21, +21p+?, +22, +22, + mar 1, + mar 2. 
52 
Case П.: Mode 77. Range 46-87. 
Four G-banded and two C-banded metaphases were analyzed. Consistent 
features were: an extra Iq- [del (l)(ql2?)], a large 1 lp+ chromosome composed 
of most of chromosome # 1 1 and the long arm of # 1, including the centromere. 
Between these two chromosome parts, a HSR was present. The probable 
composition of this marker was: llqter—»pl4?;HSR;lpl2?—» Iqter. 
Eleven markers varying in length from the A- to G-group were present. 
Most chromosomes were present in tripUcate, except for # 2, # 4, # 8, # 10, 
which were normal, and # 22 showing four copies. 
The modal karyotype was most probably: 77,XX, + 1 , +lq-, + 3 , +5?, +6, 
+7, +9, + l l p + , +12, +13, +14, +15, +16, +17, +18, +19, +20, +21, 
+22, + 22, + marl , + mar2, + mar3, + mar 4, + mar5, + mar6, + mar 7, 
+ mar 8, + mar 9, + mar 10 + mar 11. 
Case 12.: Mode 71. Range 53-76. 
Two metaphases were completely and three partially karyotyped after G-
banding. Two C-banded cells were available. Striking features were: lq-(q22), 
2q-(ql4), 5p+, 8p+, 10p+, 12p+. 
Fourteen marker chromosomes, varying in length from the A- to G-group were 
present. 
The modal karyotype was most probably: 71,XY, + X q + , + 1 , +lq-, +2q-, 
+ 3,-4,5p+,+7,8p+, + 1 0 p + , + l l , 1 2 p + , + 1 3 ? , +17, + 17, +21, + m a r l , 
+ mar 2, + mar3, + mar 4, + mar 5, + m a r 6, + mar7, + т а г 8 , + mar 9, + 
mar 10, + mar 11, + mar 12, + mar 13 + mar 14. 
Case 13.: Mode 73. Range 63-79. 
Five G-banded and two C-banded metaphases were analyzed. Consistent 
features were two, and in some cells three, 9q+ chromosomes. It appeared that 
these derivative chromosomes showed two centromeres, one of which was 
suppressed [psu die (9)]. An isochromosome i(2q) and two markers were 
present. 
The modal karyotype was most probably: 73,X,+X,-Y, + 1 , + 1 , -2, +i(2q), 
+6, +6q-, +7, +8, +8, +psu die (9), +psu die (9), +10, +11, +11, +12, 
+ 12, +13, +13, +14, +14, +15, + 15, +17, +18, +18, +19, +20, +mar 1, 
+mar 2. 
Discussion 
As reported in a previous study, non-infiltrating bladder tumors mostly have a modal 
chromosome number and a chromosomal range in the near diploid region, whereas 
infiltrating cancers mostly show hyperdiploidy [9]. 
In this study representative karyotypes of the modal chromosome numbers or 13 G-
banded tumors are given. 
In three (cases 5,6 and 13) of the ten males the Y chromosome was missing. In bone 
marrow this is frequently observed and could be an age dependent phenomenon [ 10]. The 
ages of our three patients where 54,73 and 90 years, respectively. In three of four primary 
gastric cancers, recently published, the Y chromosome was missing. The age of these 
patients was 27, 68, 54 years, respectively, whereas in the fourth patient, age 74 the Y 
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chromosome was present [11]. Our data suggest that the loss of the Y chromosome is not 
merely related to age. 
The autosomes most frequently involved in structural and/or numerical aberrations are in 
numerical sequence: 
Chromosome # 1 : This chromosome was involved in structural rearrangements in 6 cases 
(Table 2) (Fig. 1). Also, in published series of bladder cancer, chromosome # 1 frequently 
underwent structural changes [2, 3,12-14]. Furthermore, abnormalities of # 1 are 
reported as occurring in various other types of human neoplasia [15-19]. However, there 
is much variation in the position of the breakpoints. The eleven recognized breakpoints in 
the cases of bladder cancer, cited above and in our cases, are between lp22 and lq25, i.e. 
in the proximal regions of the chromosome arms, consisting of approximately of half of 
the entire chromosome. 
Chromosome # 2 showed structural changes in four cases: in three a deletion of part of the 
q-arm and in one an i(2q) were observed. The involvement of chromosome # 2 is not 
striking in the reports of previous authors dealing with bladder tumors. On the other hand 
in malignant melanoma structural aberrations of # 2 are frequent [19]. 
Chromosome # 3 was involved in a structural change in one case and in four other cases it 
was present in triplicate. 
Chromosome # 6 was frequently involved. In case 9 a translocation, t(l ;6) (pl2;pl2), and 
in case 8 a translocation t(3;?;6)(pl3;HSR;ql3), were seen. Trisomy 6 was present in four 
near triploid cases. In the study of Gibas et al. [3] chromosome # 6 was affected in five of 
the nine tumors, mostly as a deletion of the long arm. Deletions of the long arm of 
chromosome # 6 are often found in malignant disorders [20]. Involvement of chromosome 
# 6 in structural or numerical alterations of the karyotype, was accompanied by other 
chromosomal changes in all cases including ours. Thus we agree with other authors [3, 
21]. that abnormalities of chromosome # 6 most likely are secondary changes. 
Chromosome # 7 was involved in structural rearrangements in one case and in the five 
near triploid tumors as an additional chromosome. Trisomy # 7 has been reported as a 
possible primary change in TCC of the ureter [4]. In bladder cancer this change was 
present in two near triploid cases of Atkin and Baker [2] and in one near diploid and one 
near triploid case of Gibas et al. [1,3]. Because trisomy # 7 was absent in our near diploid 
cases and absent in all (except one) near diploid bladder tumors of the studies cited above, 
we tend to consider trisomy # 7 as a secondary change. 
Chromosome # 8 was involved in structural changes in two cases. An isochromosome 
i(8q), as in our case 4, has been reported before by Gibas et al. [1, 3] in two cases. 
Chromosome # 9 was involved in five of the eight near diploid cases: (9q-; -9; 9q-l- ; -9; -9, 
-9, +t(7;9) respectively). Atkin and Baker [2] found a missing # 9 in three of six near 
diploid bladder tumors and in one of four strongly hyperdiploid ones. 
Gibas et al. [1] reported monosomy # 9 in three of six near diploid tumors and in one of 
three near tetraploid cases. In the following study of this authors [3] monosomy # 9 has 
been reported in one of four near diploid cases. 
Berger et al. [4] found a missing # 9 in two of six near diploid cases. The case described by 
Kovacs [ 13] and the diploid case examined by Vanni et al. [22] also showed a missing # 9. 
Taken together, the cited studies and our data, in 14 of 32 near diploid bladder tumors 
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chromosome # 9 was missing and in two other cases a structural aberration was recognized 
(Table 3). It is more and more likely that loss of chromosome # 9 is a primary change in 
bladder tumor. 
In two cases a deletion of the long arm of # 10, breakpoint at q22, was present. This is very 
interesting since Gibas et al. [1] and Berger et al. [4] each reported a patient with a deletion 
of 10q(24). The deletion in one of our cases was the sole abnormaHty, in the other it was 
accompanied by monosomy # 9. 
Deletion of # 10 could be a primary change, since it was found in two near diploid tumors. 
Chromosome # 1 1 was involved at least three times in structural rearrangements; in one 
case with a near diploid chromosome count and in two near triploid cases. Thus, it appears 
to us, that chromosome # 11 is preferentially associated with invasiveness and that it is not 
involved in the initial steps of carcinogenesis of the bladder. Atkin and Baker [2] reported 
frequent structural changes of # 11, including short arm deletions. This could be of 
interest since the oncogene c-Ha-raf 1 is located on 1 lpl4 [23]. In our cases we were unable 
to recognize the breakpoint in # 11 rearrangements. 
Deletions of 1 lp are well known to occur in tumor cells of patients with Wilms' tumor 
[24]. 
Two of our cases (cases 8 and 11) contained homogeneously staining regions (HSR). This 
phenomenon has been described in a variety of tumors and is related to gene amplification 
[25,26]. It may be a reaction of exposure to drugs [27]. However, our cases were primary 
tumors and the patients did not receive chemotherapy before resection of the tumors 
mentioned. 
Atkin and Baker [2], using a direct technique, revealed involvement of chromosome #11 
as structural change in all six near diploid cases. In the eight cases examined by Berger et 
al. [4], data obtained after enzymatical disaggregation of the specimens and culturing the 
malignant cells, no involvement of # 11 was seen. Our results show an abnormal 
chromosome # 11 in one of the near diploid tumors. 
The simultaneous application of both methods, to more tumors is necessary to draw 
conclusions about the significance of chromosome # 11 in bladder carcinogenesis. 
Chromosome # 1 7 had undergone structural aberrations in two cases and was present in 
three or more copies in all near triploid cases. The involvement of this chromosome has 
been reported before [2]. 
In one case an additional chromosome # 20 was seen as a sole abnormality. In a resection 
specimen obtained six months after the first, the same karyotype was present. Atkin and 
Baker [2] reported on the presence of one or more extra # 20, together with other 
chromosomal changes. Berger et al. [4] reported this in two bladder tumors, but an extra 
# 20 was even more frequently found in renal tumors. They interpreted trisomy # 20 as a 
possible secondary change. 
Our findings confirm those of others in some cases, but it is also clear that differences were 
observed. The most obvious example is the absence of i(5p). This isochromosome was 
reported by Gibas et al. [ 1,3] in 7 out of 16 tumors. It cannot be established with certainty 
that i(5p) was missing in our study. For instance, in case 8 a small metacentric 
chromosome was present which resembles i(5p) or a deletion of 5q at ql3. However, both 
copies of chromosome # 5 present were normal. 
55 
In some cases normal diploid cells were present. Presumably, they represent normal 
stromal, epithelial or muscle cells. 
The number of translocations found in this study was low. Furthermore, different 
breakpoints in different chromosomes were involved. Therefore, specific translocations 
were not observed. 
Reciprocal translocations characterise several forms of leukemia and lymphoma and 
contribute to the process of neoplastic transformation by activating oncogenes situated 
close to the breakpoints [21, 28, 29]. Solid tumors in contrast, generally present 
unbalanced chromosomal changes, rather than reciprocal translocations. This results in 
duplication or loss of (parts of) chromosomes [30]. This mechanism is relevant for the 
acquisition of cancer genes in hemizygous form. As suggested by Knudson [31] invisible 
mutations - which can lead to homozygoty for recessive cancer genes - or loss of genetic 
material by deletion of (a part of) the chromosomes - which leads to hemizygoty of the 
recessive cancer gene - can produce cancer, as demonstrated in Wilms' tumor and 
retinoblastoma. Further support for Knudson's model has been obtained at the DNA 
level [32]. 
To find chromosomal changes which are specific or directly related to the origin of the 
tumors, near diploid tumors are needed, with preferably a few or ideally one chromosome 
abnormality. In spite of the problem of many chromosome abnormalities in poorly 
differentiated tumors, it is worthwhile to examine these tumors as well, since possible 
specific rearrangements could be found, which are indicators for aggressiveness of the 
tumor [28]. 
To establish the primary chromosome change, direct cytogenetic examination offers the 
best chance of success, in spite of the fact that after culturing the cells, banding of the 
chromosomes is better. Chromosomal changes in vitro and growth advantage of a special 
cell line include the risk of contradictory data. 
This study stresses loss of chromosome # 9 as a probable primary change. Deletion of 
chromosome lOq at band q22 is possibly another primary change. 
If more well differentiated transitional cell carcinomas of the bladder are chromosomally 
analyzed, it might be possible to divide bladder cancer in subgroups analogous to the 
situations in the acute leukemias. 
Prospectives in the field of therapeutic approaches and clinical behavior of the tumors also 
may be improved. 
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Table 1. 
Summary of the clinical data, range and modal chromosome number. 
case 
1. 
2. 
3. 
4. 
5. 
6A. 
B. 
7A. 
B. 
8. 
9. 
10. 
11. 
12. 
13. 
age 
74 
64 
80 
33 
73 
54 
55 
74 
74 
87 
74 
79 
67 
69 
90 
sex 
M 
M 
M 
M 
M 
M 
M 
M 
M 
F 
M 
F 
F 
M 
M 
stage/grade 
TaG2b 
TaG2a 
TaG2a 
TaG2b 
Ta(m)G2a 
Tl(m)G2a 
TaG2b 
TlG2b 
TlG2b 
T2G2b 
T2G3 
T2G2b 
T3G3 
T3G3 
T3G3 
range 
43-90 
46 
44^5 
47 
42-46 
41-72 
41-75 
44-86 
45-83 
41-86 
52-63 
64-120 
46-87 
53-76 
63-79 
chromosomes 
т . п . 
46 
46 
45 
47 
46 
44 
44 
47 
47 
42 
60 
83 
77 
71 
73 
т.п. = modal number of chromosomes. 
(m) = multiple tumors 
Table 2. 
Summary of the most 
case 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
т.п. 
46 
46 
45 
47 
46 
44 
47 
42 
60 
83 
77 
71 
73 
frequently im 
1 
+ l p -
+ l p -
+t(l;6) 
+ 
+ 1 
+ l q -
+ 1 
+ l q -
+ 1 
+ 1 
+ 1 
•olved chroi 
3 
- 3 
t(3;II;6) 
+3 
+3 
+3 
+ 3 
+3 
nosomes and their abnormalities. 
7 
- 7 
t(7;9) 
+7 
+ 7 
+7 
+7 
+7 
9 
9 4 -
- 9 
9q+ 
- 9 
- 9 
- 9 
t(9;17) 
+ 9 q -
+9 
+9 
+9q+ 
+9q+ 
10 
lOq-
lOq-
-10 
+ 10 
+ 10 
+ 10p+ 
+ 10 
11 
l l p + 
+ l l p + 
+ 11 
+ 11 
17 
-17 
+ 17 
+ 17q+ 
+ 17 
+ 17 
+t( l l ;H; l ) + 17 
+ 11 
+ 11 
+ 11 
+ 17 
+ 17 
+ 17 
Table 3. 
Summary of the near diploid tumors and the most frequently involved chromosomes. 
A. Culture method: 
authors) 
Gibas '84 
Gibas '86 
Berger '86 
В. Direct method: 
authors) 
Vanni'85 
Kovacs '85 
Atkin'85 
This study 
all 
turn. 
9 
7 
8 
all 
tum. 
2 
1 
10 
13 
dipi. 
tum. 
6 
4 
6 
dipi. 
tum. 
1 
1 
6 
8 
case 
1 
2 
3 
5 
6 
7 
1 
2 
3 
5 
1 
2 
3 
4 
6 
7 
case 
1 
1 
1 
2 
3 
4 
5 
6 
1 
2 
3 
4 
5 
6 
7 
8 
т . п . 
48 
45 
44 
47 
47 
45 
45 
47 
43 
48 
46 
45 
46 
46 
46 
47 
т . п . 
49 
46 
42/3 
42/5 
44/5 
46 
46 
46 
46 
46 
45 
47 
46 
44 
47 
42 
1 
P+ 
q + 
p + ; q -
1 
q-
+i>-
+ p -
q+ 
+i(lq) 
q+ 
+ P -
+ P -
5 
+i(5p) 
+i(5p) 
i(5p) 
q-
5 
chromosome # involved 
6 
q-
q-
q-
t(6;X) 
8 
i(8q) 
p -
p -
9 
-9 
-9 
-9 
-9 
-9;i(9q; 
-9 
chromosome # involved 
6 
+6 
q-
-6 
8 
-8 
p -
i(8q) 
t(3;H;6) 
9 
-9 
-9 
-9 
-9 
-9 
q-
-9 
q + 
-9 
-9;-9; 
t(7;9) 
t(9;17) 
1 
10 
P+ 
q+ 
q-
1 
q-
10 
-10 
-10 
q-
q-
11 
-11 
p-;p+ 
t(ii; i3) 
q-
11 
P+ 
i(llq) 
t(ll;14) 
-P 
q+ 
p -
r(l l) 
P+ 
AH turn. : patients examined; near diploid and strongly hyperdiploid tumors. 
dipi. tum. : number of tumors with a near diploid chromosome number. 
т.п. : modal number. 
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chromosome # 1 chromosome # 9 chrom # 10 
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9 9 q + 
· · 
10 10 q-
10 10 q-
Figure 1 
Structural abnormal G-banded chromosomes derived from # 1, # 9, # 10 and two HSR containing 
chromosomes. In a number of cases the C-banded chromosomes are placed on the right side. 
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Abstract 
Presence or absence of blood group isoantigens (BGI) in 78 cases of transitional cell 
carcinoma of the bladder was correlated with tumor stage and grade and results of 
chromosomal analysis. For BGI detection the indirect immunoperoxidase method with 
monoclonal antibodies to А, В and H antigen was used. In 51 percent of the 59 superficial 
tumors blood group isoantigens were demonstrable, whereas all deeper infiltrating and 
higher graded tumors were BGI negative. However in superficial tumors the mode of BGI 
expression did not correlate significantly with tumor recurrence and progression. 
Although a consistent correlation was demonstrated between chromosomal numbers and 
clinical course, the chromosomal abnormalities found and mode of BGI expression, even 
in combination, had no prognostic value additional to the grading criteria used. Of 7 
superficial tumors the karyotype could be analyzed. 
Introduction 
Superficial transitional cell carcinomas (TCC) of the bladder with identical histopathology 
can vary significantly in their subsequent clinical course. ' A significant degree of inter-
and intra- observer variability especially in the evaluation of tumor grade is reported.2 
Blood group isoantigen (BGI) deletion and chromosomal abnormalities are mentioned as 
prognostic parameters additional to tumor stage and grade.3 '4 With respect to BGI content 
and tumor behavior in bladder cancer contradictory results have been published. 
According to some authors, loss of these antigens occurs especially in tumors which carry 
a poor prognosis with respect to invasion and metastasis. ^5"7 Other authors observed that 
a significant number of invasive urothelial cell carcinomas was strongly positive for A, В 
and H antigens.8'9 These differences might be accounted for, at least in part, by the 
method used.7 '1 0 The initial studies on BGI-deletion employed the specific red cell 
adherence (SRCA) test.5 Later, the indirect immunoperoxidase method was introduced.7 
The reproducibility of this technique has been limited by the need to use a lectin in 
detecting the H isoantigen, together with variation in specificity found with conventional 
polyclonal blood group antisera. 
The availability of monoclonal antibodies (McAb's) has led to the production of highly 
specific reagents especially superior in the demonstration of the H isoantigen. In previous 
studies a correlation between increased chromosomal numbers and tumor invasion and 
grade ' ^ 1 2 was shown (this thesis chapter II, III and IV). In the present study the presence 
or absence of blood group antigens is correlated with tumor grade and stage and 
chromosomal abnormalities. In addition follow up in patients with a superficial bladder 
tumor in relation to BGI expression is studied. 
Materials and methods 
The initial biopsies from 78 patients presenting with a primary urothelial cell carcinoma of 
the bladder between 1980 and 1987 were studied (see table 1). Staging was done according 
to the T.N.M.-system.13 Tumors were called grade 1 if they showed increased cellularity 
with or without slight cellular and nuclear variations. Grade 2 tumors according to the 
criteria used showed increased cellularity, clear cytologic deviation and a tendency to loose 
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Table 1 
Distribution of stage and grade among analyzed tumors 
Tumor grade 
Grade 1 
Grade 2 
Grade 3 
Total 
Ta 
29 
9 
38 
Tumor Stage 
Tl 
1 
15 
5 
21 
T2-4 
8 
11 
19 
Total 
30 
32 
16 
78 
the normal polarity. Grade 3 applied to tumors with the most severe degree of cellular 
dysplasia. 
When progression in tumor stage was seen, or treatment was done with chemotherapy, 
immunotherapy or radical therapy, patients were excluded from further follow up. 
Determination of blood group isoantigens 
Determination of ABH blood group isoantigens was done with the indirect 
immunoperoxidase method 14 with the use of monoclonal mouse anti-Α (Dako A 571), 
anti-B (Dako A 581) and anti-Η (Dako A 582) antibodies. 
Paraffin sections cut a 5 μτα, were deparaffmized and, after blocking endogeneous peroxidase activity with 0.3% 
H2O2 in absolute methanol, rchydrated and washed in phosphate-buffered saline solution (PBS). The sections 
were then incubated for 15 minutes with normal rabbit serum (NRS) 20% in PBS to block non-specific antigen 
sites. After rinsing in PBS, sections were incubated overnight at 4° С with the appropriate McAb, diluted 1 100 
in 1% bovin serum albumin (BSA) in PBS, pH 7.2 After washing in PBS twice for 15 minutes each time, the 
sections were incubated with rabbit anti mouse immunoglobulin horse-radish peroxidase (HRP) conjugated 
(Dako Ρ 260) 1:20 m 1 % BSA in PBS The tissue sections were then washed twice in PBS followed by incubation 
in diaminobenzidine, DAB (0 05% DAB + 0.01% H
z
02 in PBS pH 7 6), washed and counlerslained with 
Haematoxyline Mayer. After washing in tap water the sections were dried and mounted with Permount. 
Tumors were considered positive for B.G.I, when by microscopic examination distinct 
tumor cell membrane staining could be discerned in at least 5% of the cancer cells in a 
slide. Positive and negative controls were used as described by others.14 In mucosal 
biopsies from 3 patients none or only very faint staining of normal urothehum in non 
tumor bearing areas was seen. These patients were not included in this analysis as they 
were probably nonsecretors. Examination of the slides was done independently and since 
1983 prospectively by two pathologists, unaware of the results of chromosomal analysis 
and follow up of the tumors. 
Chromosomal analysis 
For chromosomal analysis the direct method and, in most cases, short term culture as well, 
was used.15 Staining was done with Giemsa. If sufficient good metaphases were available, 
banding methods were used. Analyzable metaphases were karyotyped according to the 
Denver nomenclature.16 
Unless otherwise mentioned, statistical analyses were done with the chi square test. 
65 
Results 
Blood group antigen - antibody reaction 
The use of the immunoperoxidase method with the appropriate McAb's resulted in all 
analyzed cases in the formation of a distinct brownish red staining of the cell membranes 
of normal urothehum, vascular endothelium and erythrocytes, used as internal controls 
(see fig. 1). Background staining was very low. In tumor tissue, the pattern of blood group 
antigen-antibody staining appeared variable. In superficial tumors an antigen-antibody 
reaction varied from the typical staining pattern in all malignant cells to staining of only a 
few cells of the basal or, in others, the luminal layer (see fig. 2). In addition, the intensity 
of staining was not uniform. In tumors classified as BGI- positive, the surface area with 
membrane staining ranged from 5 to 90 per cent (see table 2). The difference in mode of 
BGI expression regarding tumor surface area between non-invasive and invasive as well as 
between low grade and high graded tumors, as shown in table 3, is highly significant (p = 
0.001). 
Table 2 
Distribution of estimated tumor surface area with BGI-expression according to tumor stage and grade 
Tumor surface area 
percentage positive 
0 
5-9 
10-19 
20-29 
30-39 
40-49 
50-90 
Total 
TaGl 
9 
1 
8 
2 
5 
2 
2 
29 
TaG2 
6 
1 
1 
-
1 
-
-
9 
Tumor 
TlGl 
1 
-
-
-
-
-
I 
stage and grade 
T1G2 
9 
2 
1 
2 
1 
-
-
15 
T1G3 
5 
-
-
-
-
-
-
5 
T2-4 
19 
-
-
-
-
-
-
19 
Table 3 
Correlation between BGI-expression and tumor stage and grade 
BGI expression 
Positive 
Negative 
Ta 
23 
15 
Tumor 
Tl 
7 
14 
stage 
T2-4 
19 
Gr~-
21 
9 
Tumor grade 
G2 Gi 
9 
23 16 
Cytogenetic Analysis 
With respect to the chromosome number (mode and range) we found a significant 
difference between non-infiltrating and low grade tumors on the one side, and infiltrating 
or higher graded tumors on the other side (p < 0.001 ; table 4). In infiltrating, grade 2 and 
grade 3 tumors nearly always cells with more than 49 chromosomes were found, even if 
the modal number was (near) diploid (p < 0.01). Although marker chromosomes, found 
by routine chromosomal analysis, were significantly more frequently seen in tumors of 
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Fig. 1 TCC stage Tl grade 2. Normal urothelium, vascular endothelium and erythrocytes positive 
immunoperoxidase staining for blood group substance; tumor neg. (χ 250, counterstaining with haematoxyline 
Mayer). 
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Fig. 2 TCC stage Та Grade 1 showing immunoperoxidase staining for blood group substance; only cells of the 
basal layer are positive (x 250, counterstaining with haematoxyline Mayer). 
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higher stage (ρ = 0.06) or grade (ρ = 0.0001), they were also often found in low stage, low 
grade tumors (see table 4). 
With direct method and G- and C-banding methods, the karyotype of 7 superficial tumors 
could be analyzed (see table 5). In 4 of these tumors chromosome number 9 was involved. 
In two cases a deletion of the long arm of chromosome number 10 was found, in two other 
male cases chromosome Y was missing. 
Relation of BGI-expression with Chromosomal Analysis 
No significant correlation between BGI-expression and modal number (p = 0.59), 
chromosomal range (p = 0.13) or presence or absence or marker chromosomes (p = 0.26) 
was demonstrable in superficial tumors. 
Correlation of tumor markers with clinical course 
Thirty three patients with a non-infiltrating tumor were évaluable for analysis with respect 
to clinical course (see table 6). Follow up was 12 to 66 - mean 34 - months. The percentage 
of patients free of recurrences or tumor progression was consistently lower among patients 
with a grade 1 tumor, and among tumors with (near) normal chromosomal numbers. No 
significant difference was demonstrable in clinical behavior whether or not blood group 
antigens were present in the initial tumor. Tumor progression was seen in 2 patients in 
which 30 per cent of the tumor surface area was clearly BGI positive. 
Most patients with a Tl grade 2 lesion were, after initial tumor resection or after their first 
recurrence, treated with intravesical chemotherapy or immunotherapy and thus not 
available for further follow up. Of the remaining 7 patients, progression was seen in 4 
within 4 to 8 months. In 2 of these patients the initial tumor was BGI positive. 
The correlation of tumor grade and chromosomal numbers in combination with BGI-
expression with respect to progression in non-infiltrating cancers is shown in table 7. 
Statistical analysis (within a logistic Unear regression model) of the figures presented in 
this study shows that, with respect to the occurrence of recurrences or tumor progression, 
the number of chromosomes, presence or absence of marker chromosomes, or the mode 
of BGI-expression had no prognostic value additional to tumor grade. 
A summary of the detailed histopathologic and cytogenetic data for individual bladder 
tumor patients is as an addendum added to this report. 
Table 4 
Tumor stage and grade in relation to cytogenetic data 
Tumor 
stage and grade 
Ta 
Tl 
T2-4 
Grade 1 
Grade 2 
Grade 3 
«49 
33(12)* 
9( 6) 
6( 1) 
29( 8) 
17(10) 
2 (0 ) 
mode 
>49 
5(4) 
12(8) 
13(8) 
1( 0) 
15(13) 
14( 8) 
Chromosome number 
range 
«49 
29(8) 
26(5) 
3(3) 
>49 
9( 8) 
21(14) 
19(9) 
4 (3 ) 
29(20) 
16( 8) 
( )* number of tumors with marker chromosomes. 
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Table 5 
Mode of BGI expression and karyotype in 7 superficial tumors 
Case 
6 
7 
Sex 
M 
M 
M 
M 
M 
M 
M 
T-G 
TaGl 
TaGl 
Ta(m)Gl 
TaG2 
Tl(m)Gl 
TlCi2 
T1G2 
BGI 
Expression 
neg. 
10% pos. 
neg. 
neg. 
neg. 
neg. 
neg. 
Karyotype 
46,XY,9q-,-12, + mar. 
45,XY,-9,del(10)(q22) 
46,X,-Y, + lp-
47,XY,2q- ;+i(8q))9q + 
44,X,-Y,+lp- , -9, l lp+,-14 
46,XY,del(10Xq22) 
47 )XY,+20. 
Tableó 
Correlation of tumor markers with follow up* for Ta tumors 
Chromosomal BGI 
Number of 
patients 
Grade Mode Range Marker Expression 
1 «49 >49 « 4 9 >49 + + 
27 6 30 3 26 7 21 12 21 12 
15(56) 1(17) 16(53) 0 14(54) 2(29) 12(57) 4(33) 12(57) 4(33) 
Evaluable 
Disease free(%) 
Non-invasive 
recurrence(%) 10(37) 3(50) 11(37) 2(67) 10(38) 3(42) 8(38) 5(42) 7(33) 6(50) 
Tumor progression(%) 2( 7) 2(33) 3(10) 1(33) 2( 8) 2(29) 1( 5) 3(25) 2( 9) 2(17) 
Recurrence rate 2.5 4.2 2.8 2.0 2.8 2.8 2.0 4.0 2.4 3.4 
* Follow up varying from 12 to 66 - mean 34 - months. 
Table 7 
Correlation of tumor markers in combination, with progression, in 35 patients with TCC stage Ta 
No of patients 
Chromosomal 
mode range markers 
BGI expression 
positive* negative* 
Grade 1 
Grade 2 
BGI pos.* 
BGI neg.** 
« 4 9 
26/21 
4/1 
21/2 
9/1 
>49 
1/0 
2/1 
0/0 
3/1 
« 4 9 
24/1 
2/1 
18/1 
8/1 
> 4 9 
3/1 
4/1 
3/1 
4/1 
no 
21/1 
0/0 
14/1 
7/0 
yes 
6/1 
6/2 
7/1 
5/2 
19/2 
2/0 
8/0 
4/2 
1
 Values are given as number of patients evaluable/numbcrs of patients with tumor progression. 
Follow up 12 to 66 - mean 34 - months. 
Discussion 
Several technical problems regarding detectability of blood group antigens and 
reproducibility of test results made widespread clinical application of BGI-analysis 
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inappropriate. It was hoped that the use of monoclonal antibodies might solve some of the 
problems.9,17 In our study false negatives were ruled out by the presence of strongly 
positive internal controls. Patients in whom no staining of normal urothelium was seen, 
were excluded from this study. Probably these patients were nonsecretors. The expression 
of blood group specificities in normal (secretory) epithelium and in epithelial tumors is 
strongly related to the secretor status of the person.18,19 In urothelium, the А, В and H 
antigens are present in much lower amounts or even absent in the 15-20 per cent 
nonsecretor persons. That means a restriction in the clinical usefulness of ABH 
antigenicity in bladder tumors. 
A major problem is how the test results should be quantified. Interpretation of the BGI 
test is subjective and is not as straight forward as indicated in many reports. Loss of blood 
group antigens is not an "all or none" phenomenon.20 Often an incomplete reaction is 
seen, indicating presence of antigens in some areas and absence in other areas in the same 
block of paraffin embedded tissue or even in the same field. The detectability of BGI can 
be influenced not only by the method of tissue processing and the type of anti-sera, but 
also by inherent differences in the quantity of BGI on the tumor cell surface.8,20,21 The 
action of malignant cells might be to suppress to a variable extent the conversion of H to A 
and В antigens and perhaps the formation of H from precursor substance.8 The 
intratumor heterogeneity of blood group antigen expression complicates the 
interpretation of test results regarding BGI deletion which is another restriction for the 
clinical usefulness of ABH-antigen measurements. Because of the inherent variability in 
staining reaction, it is not surprising that various authors have differed in their definition 
of a positive test result (i.e. BGI retention). Since the results of both the specific red cell 
adherence (SRCA) test and immunoperoxidase methods are based on semiquantitative 
evaluations of light microscope preparations, the cutoff point for non-reactivity can not be 
objective. Weinstein and associates22 stated that tumors with less than approximately 30 
per cent of the cells expressing the ABH antigens as shown with polyclonal antibodies have 
the same high probability to invade the bladder wall as those with no antigen staining. 
Giraldo and associates 9 established the 30 per cent criterion after determining that the 
degree of background staining never exceeded 30 per cent. In a study on BGI deletion with 
monoclonal antibodies in cervical carcinoma it was shown that cases with positive staining 
in beWeen one and 30 per cent of cells, showed the same survival as the more positive 
cases.
23
 In our material with a threshold for positivity as low as 5 per cent all BGI positive 
tumors were non- or only superficially invasive, whereas all deeper infiltrating and all 
grade 3 carcinomas were negative for ABH antigen. So a good correlation between test 
results and tumor stage and grade was demonstrable. 
With respect to tumor recurrences and progression in superficial tumors, we could not 
find a consistent difference between BGI positive and BGI negative tumors, irrespective 
of the threshold for positivity. Tumor progression was seen in BGI positive as well as in 
BGI negative tumors. Other authors also concluded that evaluation of blood group 
antigens could not be equated to biological behavior in transitional cell carcinomas.8,9,24"26 
The lack of an absolute correlation in their studies, like in our own, is rather significant, 
thus eliminating the use of this technique in treatment planning for the individual patient. 
It has been proposed that the loss of blood group antigens in cystoscopically normal 
epithelium may represent one of the earliest measurable changes of the malignant 
potential of the urothelium.27,28 ABH antigenicity of normal looking epithelium was 
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mentioned to be a better predictor of recurrences the first year after initial diagnosis than 
other prognostic indices including tumor grade and histological status of the mucosal 
biopsies.28 The predictive value of ABH antigenicity of mucosal biopsies with respect to 
tumor progression is still unknown. 
When more is known about the genetics and biochemistry of ABH antigens and their 
precursors in normal and neoplastic epithelial cells, perhaps a precursor substance is 
found, common to all individuals, irrespective of the ABO and secretor types. 
Determination of presence or absence of a common precursor might increase the 
prognostic accuracy of blood group antigen analysis in bladder cancer.29 
Immunohistochemical studies have also explored the relation between the expression of 
other blood group antigens and the biological behavior of bladder cancer. With respect to 
the Thomsen Friedenreich antigen, conflicting results have been reported. ' l ù 31 The 
prognostic significance of Lewis a and Lewis b antigens in superficial bladder tumors still 
has to be defined.32 
Cytogenetic analysis of bladder cancer showed that low grade and noninvasive tumors 
generally have hypo- or peridiploid chromosomal numbers.4,12 In high grade tumors 
hyperdiploid modal numbers are found. Intermediate grade tumors often are 
characterized by (near) modal numbers, but as we showed before,12 in these tumors nearly 
always hyperdiploid cells are demonstrable. Thus the range in chromosomal numbers 
appeared to be an objective basis for grading. From the present study it appeared that the 
finding of marker chromosomes, unidentified structurally abnormal chromosomes, has 
no prognostic value additional to tumor grade or chromosomal range. In our view the 
finding of marker chromosomes is to a high degree dependent on technical methods. 
Identification of chromosomes by banding methods is needed to evaluate whether specific 
chromosomal abnormalities are related to future mahgnant behavior of the primary tumor 
analyzed. 
A detailed study about our results with chromosome banding methods in infiltrating and 
non-infiltrating bladder cancers is reported elsewhere. " In 4 of the 7 superficial tumors in 
which we were able to analyse the karyotype, chromosome number 9 was involved. The 
genes for the ABO blood groups are located on chromosome 9.34 Loss of chromosome 9 is 
often reported in bladder tumors35"38 and might be a primary change in urothelial cell 
carcinoma.32 We found various karyotypes at first diagnosis by direct method, probably 
indicating the existence of subtypes of bladder tumors. Follow up of these karyotyped 
tumors is as yet to short to evaluate a prognostic meaning. 
Chromosome analysis and mode of BGI expression are claimed to be the most reliable 
tumor markers for bladder cancer.4,39 From the present study it is clear that, with respect 
to future tumor behavior, the chromosome number, chromosomal markers, and the 
presence or absence of ABH blood group expression have no prognostic value additional 
to tumor grade with the grading criteria used. So far tumor stage and grade remain the 
hallmarks in assessing the malignant potential of superficial transitional cell carcinoma of 
the bladder. 
Dr W Doesburg and A. Remtjes, University of Nijmegen, performed statistical evaluation, miss L Laarakkers 
supplied technical assistance; Drs J Scheepers and R Reterà and the members of the Operating Room provided 
cooperation 
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Blood Group Isoantigen Deletion and Chromosomal Abnormalities in Bladder Cancer Addendum -1 
Histopathologic and cytogenetic data of individual bladder tumor patients 
Patient Tumor Chromosomal Follow up 
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radiotherapy + cystectomy 
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radiotherapy 
death unrelated to cancer 
radiotherapy 
cystectomy 
radiotherapy 
radiotherapy 
cystectomy 
radiotherapy 
cystectomy 
radiotherapy 
radiotherapy 
death of cancer 
radiotherapy 
radiotherpay 
1
 Blgr : bloodgroup 
2
 B.G.I, pos. : estimated percentage of tumor area in slide in which by microscopic examination tumor cell membrane staining can be seen 
3
 Ploidy : n = 2 3 ± l l ; 2 n = 4 6 ± l l ; 3 n = 6 9 ± l ie te . 
4
 Ree./Months : number of recurrences per total number of months follow up 
5
 Progression : progression in tumor stage 
Chapter VII 
General discussion 
Histopathological grading 
The most important parameters for prognosis in superficial transitional cell carcinomas of 
the urinary bladder are tumor stage and grade.1"5 Grading of these tumors lacks an 
objective basis and therefore appears to be inconsistent.6 The primary aim of this study 
was the search for parameters giving a sharper histopathological distinction between low 
and intermediate grade carcinomas. To find additional prognostic parameters we 
examined tumors cytogenetically and with respect to blood group antigen deletion. 
The cytological abnormalities considered as evidence of anaplasia are summarized in the 
WHO-booklet on grading in bladder tumors.7 Among pathologists increased cellularity 
only is generally considered as the least degree of anaplasia. This means that tumors 
showing only thickened epithelium without appreciable cellular deviations are to be 
defined as grade l.8,9 We found no difference between tumors showing only increased 
cellularity and those showing in addition more evidence of cellular atypia as some 
irregularity in size of cells and nuclei and slight polymorphism neither with respect to 
tumor stage nor to clinical course. Tumors with these abnormalities in otherwise 
cystoscopically normal bladders, were mostly non-invasive and not accompanied by signs 
of severe dysplasia elsewhere in the bladder. The clinical course of these tumors appeared 
to be rather innocent. The recurrence probability within 3 years was 43 per cent, during 
the first year after initial tumor resection in non-invasive tumors only 5 per cent. Tumor 
progression was present in only 5 per cent of cases during our limited follow up of two 
years. 
In our view, the group of low grade or grade 1 transitional cell carcinomas consists of 
urothelial cell tumors showing increased cellularity with or without mild cellular atypia. 
Cystoscopic control of these tumors can be postponed till at least half a year after initial 
diagnosis, provided that only a single tumor was found. Prophylactic intravesical 
chemotherapy or immunotherapy should be reserved for those patients showing 
multifocal disease or recurrences. 
In our opinion, as grade 2 TCC ought to be considered those neoplasms showing 
microscopically thickened epithelium with distinct cellular irregularity, clear variations 
in nuclear and cellular size, quite noticeable hyperchromasia, and an evident tendency to 
loose the normal polarity of epithelial cells. These tumors can be non-invasive but in 
majority they appeared to be submucosally or deeply invasive. Sometimes they were 
accompanied by severe dysplasia in non-tumor bearing areas in the bladder. Clinically, at 
least 30 per cent of these tumors was at risk for a recurrence during the first year after 
initial treatment, which figure increased to more than 80 per cent within 3 years. Tumor 
progression was seen in one out of every three superficial tumors graded as intermediate 
according to our criteria, often rather early after initial diagnosis. 
The proposed grading criteria offer a consistent distinction between low and intermediate 
TCC with clinical relevance. The grading criteria applied in our study appeared also liable 
to some intra- and interindividual inconsistency. Quantitative morphometry has been 
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applied to try to characterize the different grades of human bladder carcinoma more 
objectively.10"13 
Chromosomal numbers 
Cytogenetic analysis of bladder tumors was done to investigate the prognostic significance 
of chromosomal abnormalities and their correlation with our histopathological grading 
criteria in TCC. Initially, with conventional staining methods recognizable chromosomes 
were found in only 45 per cent of the tumors examined (this thesis chapter II). Due to 
technical improvements, at present recognizable metaphases are found in 93 per cent of 
the tumor biopsies, irrespective of tumor stage.14 Identification of chromosome 
abnormalities with chromosome banding methods remains a problem. This regards 
especially the non-infiltrating bladder tumors where the yield of analyzable metaphases 
per tumor biopsy is usually lower than in invasive ones. Chromosomal analysis of cultured 
cells may reveal more karyotypic abnormalities.15"17 However, such a technique involves 
the risk of selection of particular cell types during culture. 
The majority of low grade and non-invasive tumors have been reported to have near-
diploid modal numbers and normal DNA values, while high grade and deeply invasive 
tumors showed frequently hyperdiploid modal numbers and abnormal DNA values.18"25 
The large group of so-called intermediate grade superficial tumors appeared to be 
heterogeneous. It is in this group that objective parameters or additional tumor markers 
are urgently needed. Till now the discriminating power of DNA cytometry is deficient in 
these tumors.26 Small numerical or structural aberrations which do not change the mass of 
DNA rigorously cannot be recognized by flowcytometric DNA analysis. By investigating 
the relation between the range in chromosomal numbers and tumor stage and grade, we 
saw remarkable correlations. All invasive tumors, even if only superficial (pTI), contained 
at least a few hyperdiploid cells, while the modal numbers often were (near) normal. 
Therefore, the range in chromosomal counts appeared to be a better reflection of invasion 
than the modal number. 
Regarding tumor grade, we found normal chromosome numbers in grade 1 tumors, in 
majority hyperdiploid modal numbers in grade 3 tumors. The group of intermediate grade 
tumors was heterogeneous with respect to modal numbers. However, these tumors nearly 
always showed a hyperdiploid chromosomal range. The correlation with chromosomal 
range gives a biological meaning to our grading system, namely a distinction between 
those superficial tumors which appear less likely to impose a risk to a patient with bladder 
cancer, and those which are biologically more aggressive. Like most solid tumors, 
individual bladder tumors often show heterogeneities, with respect to histology27 29 as 
well as with respect to ploidy30'31 and other tumor markers.24,32,33 By single-cell 
cytophotometric analysis of urothelial bladder cancer it was demonstrated that the 
superficial portion of Ta or T l tumors contained a relatively higher percentage of diploid 
tumor cells than did the deeper, basaloid regions.31 Apparently this heterogeneity of 
tumor cells is better reflected in the range of chromosomal numbers than in a sharp modal 
number. This cytogenetic heterogeneity might permit selection and increase of aberrant 
cells that are responsible for tumor progression and metastasis.34 The conclusion may be 
that in superficial bladder cancer the discriminating power of chromosomal range, with 
regard to tumor progression, is better than that of modal number and DNA-value. 
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There may have been a bias for tumors of larger size in the cytogenetically analyzed 
cancers. We needed tumor material for routine histopathological, inununohistochemical, 
cytogenetical and flowcytometrical studies. Especially during the first years of the 
cytogenetic analysis, fairly large amounts of tumor material were needed for cytogenetic 
examinations. Thus, in the beginning very small tumors were excluded from 
chromosomal analysis.35 According to some authors, large size of a bladder tumor at the 
initial assessment is associated with a poorer prognosis.3'5,36 This could explain why the 
clinical course of patients examined cytogenetically seems worse than we reported in the 
study on morphological grading criteria. 
Marker chromosomes 
Cytogenetic studies can show two kinds of chromosomal abnormalities in cancer: 
numerical and structural. Marker chromosomes belong to the latter group. They are 
structural abnormalities which cannot be identified unless specific banding techniques 
are applied. Especially in poorly differentiated and invasive bladder cancers marker 
chromosomes are frequently reported.22,37,38 Markers were regarded as a very bad 
prognostic factor.22,39'42 It was said that, in general, tumors without markers could be 
expected to behave in a noninvasive fashion, while tumors with markers could be expected 
to produce numerous recurrences and to become invasive.42 The combination of markers, 
a hyperdiploid mode and submucosal invasion should involve a lethal prognosis and 
mandate radical bladder resection.40,41 
In our study more abnormal chromosomes were found in higher graded tumors or those 
with a hyperdiploid chromosomal range. The finding of unidentified abnormal 
chromosomes had no prognostic value additional to tumor grade or chromosomal 
numbers. With respect to tumor progression no significant difference between superficial 
tumors with or without marker chromosomes was observed. Thus, in our opinion the 
finding of marker chromosomes in non-banded preparations, does not have the predictive 
value generally22,37"42 assigned to this parameter in superficial bladder cancer. The low 
frequency of abnormal chromosomes in superficial cancer as mentioned by earlier authors 
probably is due to technical shortcomings of chromosome preparations.14 
For identification of the different changes in chromosomal structure, banding techniques 
are necessary. Using these techniques, rather specific cytogenetic findings have been 
detected for a variety of solid and hemopoietic neoplasms.43'47 We apphed G-banding 
succesfully in 13 bladder tumors at first diagnosis. Seven of these were superficial tumors 
of low and intermediate grade. Chromosome # 9 was involved in four of these superficial 
cases. A missing chromosome # 9 in diploid bladder tumors has been reported by other 
authors.47"52 These data suggest that loss of chromosome # 9 may be a primary karyotypic 
change in bladder cancer. Primary chromosomal changes are possibly related to tumor 
cell etiology.53,54 In the more advanced, infiltrating, hyperdiploid tumors, we found many 
changed chromosomes. The karyotypes of these tumors were very different. Probably the 
increasing variation in chromosome number is secondary and occurs during the 
progression of the neoplasia. The correlation with more advanced tumors suggests that 
such secondary chromosomal changes contribute to the capacity of the tumor to invade, 
metastasize and kill the host. It has been suggested that these secondary chromosomal 
changes, often resulting in extra gene dosage, confer proliferative advantage to some 
clones of tumor cells.1б So far cytogenetic characterisation of aberrations that may be 
indicators for infiltration and dissemination is an objective that remains to be fulfilled. 
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The application of advanced banding techniques on non-cultured cells in larger series of 
bladder tumors with a longer follow up is needed to see what exactly is the prognostic 
significance of structural chromosomal abnormalities in bladder cancer. 
ABH antigen deletion 
At the start of this study on the ABH antigen status in bladder tumors, it was generally 
assumed that determination of ABH antigen expression in urinary bladder carcinoma had 
predictive value.55"61 With respect to tumor grade, some authors mentioned a significant 
correlation between histopathological grade and blood group antigen status.55·57'58'60 
Others reported that presence or absence of blood group antigens in bladder tumors was 
not merely a reflection of histological grade.62"66 A number of techniques was available to 
demonstrate these antigens, for instance the specific red cell adherence test55'67, the 
immunofluorescence technique68"70 and the immunoperoxidase method.61'69'71 The 
conflicting results might, at least partly, be due to differences in methodology and 
interpretation. Also the lack of uniformity in tumor grading could be of relevance. 
The availability of monoclonal antibodies might solve some of the problems of other tests, 
especially because of their absolute purity and well defined specificity. In the present 
study the ABH antigen status as found by the indirect immunoperoxidase method using 
monoclonal antibodies, was compared with tumor grade and stage. The demonstration of 
antigens by immunoperoxidase procedures depends on the development of contrast 
between the staining of the antigen and its surroundings. In cell surface studies the 
optimum concentration of antibodies is determined by the dilution beyond which further 
twofold dilution produces no additional fall in the percentage of positive cells.72 In our 
laboratory, for normal urothelium this was a dilution of the appropriate monoclonal 
antibody of 1:100. Using this concentration, we retained a high degree of sensitivity for 
normal urothelium and vascular endothelium, while background staining was very low, 
never exceeding 5 per cent. 
With this method, the pattern and intensity of blood group antigen-antibody staining in 
superficial tumors appeared very variable. All deeper invasive and high grade tumors were 
however completely ABH negative. A significant difference in BGI-expression was seen 
between low grade tumors versus intermediate and high grade tumors. Therefore the 
mode of expression of these antigens clearly reflects signs of malignant dedifferentiation. 
Significantly more superficial grade 2 tumors were negative for blood group antigens than 
grade 1 tumors. Thus it might be possible that the mode of BGI expression in superficial 
tumors has additional prognostic value. However, no consistent correlation between ABH 
status and clinical course was found, neither with respect to tumor recurrences, nor to 
progression. This confirms recent observations made by other authors.36,73 
From our study it is clear that there is a direct correlation between higher histological 
grade and loss of bloodgroup antigens. In superficial tumors the mode of BGI expression 
is variable and difficult to express on a quantitative way. As long as there is no general 
consensus about standardisation of the technique and quantitative interpretation of test 
results, the ABH antigen status in superficial TCC of the bladder cannot be used 
prognostically or therapeutically in an individual patient. 
Arranging the test results on an arbitary scale according to the percentage of cells 
considered positive for antigen staining, remains a superficial interpretation of the 
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heterogeneity of bloodgroup antigen staining in bladder tumors. Recently, a method was 
described to record the staining intensity on a score in accordance with the dilution of 
antibody needed to give a clearly positive coloration for the antibody-antigen reaction.74 
However prediction of an unfavourable course with this assay appeared not possible. It 
has been suggested that reagents recognizing bloodgroup precursor substances, common 
to all individuals irrespective of the ABO and saliva secretor types, may increase the 
prognostic accuracy of bloodgroup antigen determination in bladder cancer.74 This has to 
be investigated. 
Determinants of the А, В and H bloodgroup antigens are carbohydrate structures carried 
on both glycoproteins and glycolipids.75,76 Incomplete synthesis or partial degradation of 
olygosaccharide chains can thus result in both deletion of normal blood group antigens 
and expression of abnormal precursor substances. Biochemical analysis of these 
antigenmolecules permit quantitative analysis and precise delineation of molecule 
structures.77 A significant limitation of biochemical studies is that they require samples of 
fresh tissue, in which the amount of viable tumor tissue may be highly variable. This 
makes biochemical analysis of BGI expression in bladder carcinomas in clinical practice 
difficult to realize in a reproducible way. 
Multiparameter flowcytometric analysis of blood group antigens in tumor cells may be a 
promising technique.81 Urothelial cells in diploid tumors might be recognized by labeling 
the cell suspensions with antibodies to cytokeratins.26,83 
Alterations in the ABH antigens may occur relatively early in tumor progression. ABH 
deletion has been described in premalignant epithelium in the bladder.78"82 Blood group 
antigen deletion might thus be indicative of the presence of a malignant diathesis in 
apparently normal urothelium prior to the morphologic expression of the neoplastic 
lesion. In a recent study, ABH antigenicity of mucosal biopsies proved to be a better 
predictor of recurrent disease that other prognostic indices.73 
Immunohistochemical studies have also explored the relation between the expression of 
other blood group antigens and the biological behavior of transitional cell 
carcinoma.24'76'84"86 The prognostic significance of presence or absence of these blood 
group related antigens in superficial TCC still has to be defined. 
Probably testing for blood group related antigens in bladder cancer is more appropriate 
for making therapeutic decisions as soon as the biochemical, biophysical and cellular 
factors which influence the expression of these antigens are better understood. In 
conjunction with other tumor markers testing for blood group related antigens might then 
be of help to identify specific risk factors regarding the future behavior of a bladder tumor 
in an individual patient. 
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Chapter VIH 
Summary and conclusions 
Superficial bladder cancer has a natural course uncertainly to predict. Most important 
prognostic factors are tumor stage and grade. Aim of this study was the search for factors 
contributing to a sharper histopathological distinction between low and intermediate 
grade carcinomas and to find additional prognostic parameters. 
For this purpose, chromosomal changes, microscopic histopathology and ABH antigen-
deletion were studied. Initially, recognizable chromosomes were found in only 45 per cent 
of the tumors examined, at present due to technical improvements in 93 percent. Non-
invasive tumors nearly always were neardiploid. In all invasive cancers at least some cells 
with many extra chromosomes were found. The range in chromosomal counts appeared to 
be a better reflection of invasion than the modal number. 
In tumors with a (near)-normal chromosomal mode, those with chromosome counts up to 
the hyperdiploid range tended to behave worse than tumors with only near normal 
numbers: they recurred earlier and showed significantly more often tumor progression. 
Thus, with respect to the clinical course, the discriminating power of the chromosomal 
range was better than that of the modal number. The finding of chromosomal markers, 
unidentified structurally abnormal chromosomes, had no prognostic value additional to 
tumor stage, grade or chromosomal number. 
The data obtained with chormosome analysis using G- and C- banding suggest that the 
loss of chromosome # 9, and possibly also of the long arm of chromosome #10, is a 
primary event in the karyotypic evolution of TCC. The increase in number of 
chromosomes is probably secondary and occurs during the progression of the neoplasia. 
In a prospective study on grading of superficial bladder cancers, a histopathological 
distinction was made within the group of, initially called, intermediate grade tumors. 
According to this study tumors with some cellular variation (grade "2a") and those 
showing only increased cellularity both are to be regarded as grade 1 TCC. They behave 
significantly different from those cancers showing clear cytologic deviation and a tendency 
to loose the normal polarity (grade "2b"). Grade 1 tumors according to our criteria 
generally were noninvasive. Their chance of recurrence during the first 3 years after initial 
endoresection was less than 50 percent. If recurrence happened, it usually took place late. 
Tumor progression was seldom seen. Grade 1 tumors had near diploid chromosomal 
numbers and were mostly positive for ABH blood group antigens. 
Tumors which according to this study have to be regarded as grade 2 TCC were often 
submucosally or deeply invasive, had a recurrence probability of more than 80 percent 
within 3 years after initial endoresection, recurred often early, and showed progression in 
at least 30 percent. Tumors thus graded had chromosomal counts up to the hyperdiploid 
range, although half of them showed near normal modal numbers. These cancers were 
mostly negative for ABH blood group antigens. 
Grade 3 TCC applies to tumors with the most severe degree of cellular anaplasia. They 
were in majority deeply invasive, had hyperdiploid modal chromosome numbers, and 
were negative for ABH blood group antigens. 
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In this study the ABH antigen status, as found by the indirect immunoperoxidase method, 
using monoclonal antibodies, was compared with tumor stage and grade and clinical 
course. 
The pattern and intensity of blood group antigen - antibody staining in superficial tumors 
appeared very variable and quantitatively difficult to express. A significant difference in 
BGI-expression was seen between low grade - low stage versus intermediate or high grade 
and invasive tumors. With the method used in this study, prediction of the clinical course 
in superficial TCC according to BGI-deletion appeared not possible. 
A general consensus about standardization of the technique and quantitative 
interpretation of test results with respect to blood group related antigens in tumors is 
needed to use this assay prognostically or therapeutically in an individual patient. 
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Samenvatting en conclusies 
Het natuurlijk verloop van oppervlakkige blaastumoren is moeilijk voorspelbaar. De 
belangrijkste parameters met betrekking tot de prognose zijn stadium en graad van de 
tumor. Doel van deze studie was het zoeken naar een consistent histopatologisch 
onderscheid tussen graad 1 en graad 2 tumoren, alsmede naar andere prognostische 
parameters. Hiertoe werd chromosomaal en microscopisch histopathologisch onderzoek 
gedaan en de ABH bloedgroep antigenen expressie werd immunohistochemisch 
onderzocht. 
Aanvankelijk werden slechts in 45 procent van de tumoren beoordeelbare metafasen 
verkregen, welk percentage thans dank zij technische verbeteringen in de methode van 
onderzoek is gestegen tot 93. Niet infiltrerende tumoren bleken bijna steeds een nagenoeg 
normaal aantal chromosomen te hebben. In infiltrerende tumoren werden vrijwel steeds 
cellen met extra chromosomen aangetroffen. De spreiding van het aantal chromosomen 
bleek een betere weerspiegeling van invasieve groei te zijn dan het modale aantal 
chromosomen. 
Bij tumoren met een vrijwel normaal modaal aantal chromosomen had de aanwezigheid 
van cellen met een hyperdiploid aantal in het algemeen een slechtere prognostische 
betekenis. Dergelijke tumoren recidiveerden eerder en toonden significant vaker 
progressie. De spreiding van het aantal chromosomen heeft dus een grotere prognostische 
waarde dan het modale aantal. In tegenstelüng tot wat hieromtrent door eerdere auteurs 
werd vermeld voegde het vinden van niet geïdentificeerde, structureel afwijkende 
chromosomen niets toe aan de verwachting van de prognose op basis van stadium, graad 
en chromosomenaantal van de tumor. 
Chromosomaal onderzoek met behulp van G- en C-bandering suggereerde dat het verlies 
van chromosoom # 9 en mogelijk ook van de lange arm van chromosoom # 1 0 , een 
primaire afwijking is in de oncogenese van de blaas. De toename van het aantal 
chromosomen is mogelijk een secundaire gebeurtenis tijdens de verdere evolutie van een 
blaastumor. 
In een prospectief onderzoek betreffende gradering van het blaascarcinoom werd, naar 
microscopisch histopathologische criteria, een onderscheid gemaakt binnen de groep van 
de tot dan matig gedifferentieerd genoemde tumoren. Tumoren met geringe cellulaire en 
nucleaire afwijkingen (graad "2a") toonden klinisch een zelfde gedrag als tumoren welke 
alleen celtoename lieten zien. Dit gedrag was significant anders bij tumoren met duidelijke 
cytologische afwijkingen bij welke de normale epitheliale opbouw enigermate was 
verstoord (graad "2b"). Met betrekking tot de prognostische betekenis dienen tumoren 
welke alleen een toename van het aantal cellen vertonen en die welke daarenboven geringe 
cytologische atypie hebben, als één groep te worden beschouwd, namelijk de graad 1 
urotheelcel tumoren. Deze maligne nieuwvormingen waren in het algemeen niet 
infiltrerend. De kans op een recidief binnen 3 jaar na verwijdering was kleiner dan 50 
procent. Recidieven van graad 1 tumoren werden in het algemeen laat gezien, eerst een 
jaar of meer na endoresectie. Zij hadden een nagenoeg normaal aantal chromosomen en in 
meerderheid hun ABH bloedgroepantigenen behouden. 
Als graad 2 urotheelcel-carcinomen dienen te worden beschouwd die tumoren welke naast 
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celtoename een duidelijke variatie in vorm en afmeting van cel en kern tonen en een 
neiging hebben de normale epitheel-opbouw te verliezen. 
Zij groeiden vaak submuceus of dieper infiltrerend, hadden een recidiefkans van meer 
dan 80 procent binnen drie jaar na eerste behandeling, recidiveerden vaak al vroeg, en 
toonden in meer dan 30 procent van de gevallen progressie. Tumoren met deze mate van 
dedifferentiatie hadden in de helft van de gevallen een nagenoeg normaal modaal aantal 
chromosomen. Bij deze gevallen werden steeds cellen gevonden met een hyperdiploidie. 
Deze neoplasmata waren meestal negatief voor ABH bloedgroep-antigenen. 
Tot de graad 3 urotheelcel-carcinomen behoren tumoren welke de ernstigste mate van 
cellulaire atypie tonen. Zij waren meestal diep infiltrerend, hadden hyperdiploide 
aantallen chromosomen, en waren altijd negatief voor ABH bloedgroep-antigenen. 
In deze studie werd de wijze van expressie van ABH bloedgroepantigenen bepaald met 
behulp van de indirecte immunoperoxidase methode met gebruikmaking van 
monoclonale antilichamen. De bloedgroep antigenen-expressie werd gerelateerd aan 
stadium, graad en klinisch verloop van de tumor. Het patroon en de intensiteit van 
kleuring van bloedgroep-antigenen in oppervlakkige blaastumoren bleek zeer variabel en 
moeilijk in een exacte maat uit te drukken. Tussen niet-infiltrerende graad 1 tumoren 
enerzijds en graad 2 en 3 en invasief groeiende tumoren anderzijds, werd een significant 
verschil in BGI-expressie gezien. Voorspellen van het klinisch verloop van een 
oppervlakkige blaastumor bleek met de in deze studie gebruikte methode echter niet 
mogelijk. Standaardisatie van de methode en haar interpretatie is vereist alvorens deze 
techniek bruikbaar is met betrekking tot prognose en therapieplanning voor een 
individuele patient. 
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Stellingen 
1. Bij oppervlakkige blaastumoren levert het aantonen van hyperdiploidc cellen een 
juistere prognostische parameter dan het modale aantal chromosomen of de 
D.N.A.-waarde. 
2. Markerchromosomen zijn vooralsnog niet bruikbaar als additionele 
tumormarkers. 
3. Indien papillaire, solitaire, niet-infiltrerende urotheelceltumoren bij eerste 
diagnose niet als zodanig herkend worden, dient het nemen van multiple biopten 
uit ogenschijnlijk normaal blaasslijmvlies te worden overwogen. 
4. Bij het voornemen tot prophylactische behandeling van papillaire, solitaire, niet-
infiltrerende, goed gedifferentieerde blaastumoren met intravesicale 
chemotherapeutica of immunostimulerende agentia dient het betrekkelijk 
goedaardig verloop van de meeste van deze tumoren mede in overweging 
genomen te worden. 
5. De bruikbaarheid van het onderzoek naar het verlies van blocdgroep-antigenen 
bij het blaascarcinoom wordt ernstig beperkt door het ontbreken van 
overeenstemming omtrent de kwantitatieve interpretatie van betreffende 
testresultaten. 
6. Onder de verschillende methoden ter afleiding van de urinewegen bij een radicale 
cystectomie dient de urelcro-ileo-cutaneostomie vooralsnog de voorkeur te 
genieten. 
7. Circumcisie bij neonaten kan een belangrijke rol spelen ter preventie van 
nierinsufficiëntie op latere leeftijd. 
8. De adequate behandeling van ongecompliceerde urineweginfecties bij vrouwen 
vóór de menopauze middels kortdurende antibiotische therapie vormt meer een 
diagnostisch dan een therapeutisch probleem. 
9. Bij regionalisatie van gezondheidszorg dient een provinciegrens geen 
belemmerende factor te zijn. 
10. Het vastleggen van een studie in een proefschrift mag geen stagnerende factor 
vormen voor verder onderzoek. 
11. Het verdient aanbeveling om "Götterdämmerung" van Wagner in disco-versie 
op te nemen. 
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